Washington University in St. Louis

Washington University Open Scholarship
Arts & Sciences Electronic Theses and
Dissertations

Arts & Sciences

Spring 5-15-2022

Molecular Characterization of Integrase-RNA Interactions and
Their Role in the Replication of HIV-1 and Other Retroviruses
Christian Shema Mugisha
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds
Part of the Biochemistry Commons, and the Molecular Biology Commons

Recommended Citation
Shema Mugisha, Christian, "Molecular Characterization of Integrase-RNA Interactions and Their Role in
the Replication of HIV-1 and Other Retroviruses" (2022). Arts & Sciences Electronic Theses and
Dissertations. 2659.
https://openscholarship.wustl.edu/art_sci_etds/2659

This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open
Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an
authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Molecular Cell Biology

Dissertation Examination Committee:
Sebla B. Kutluay, Chair
Megan Baldridge
Siyuan Ding
Sergej Djuranovic
Liang Shan

Molecular Characterization of Integrase-RNA Interactions and Their Role in the Replication of
HIV-1 and Other Retroviruses
by
Christian Shema Mugisha

A dissertation presented to
The Graduate School
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

May 2022
St. Louis, Missouri

© 2022, Christian Shema Mugisha

Table of Contents
List of Figures ............................................................................................................................... iv
List of Tables ...................................................................................................................................v
Acknowledgements ........................................................................................................................ vi
Abstract of the dissertation .......................................................................................................... vii
Chapter 1: Introduction ................................................................................................................. 1
1.1 Introduction .............................................................................................................................. 2
1.2 Overview of the HIV-1 replication cycle ................................................................................... 3
1.3 HIV-1 Integrase and its catalytic Role ...................................................................................... 7
1.4 Virion Morphogenesis ............................................................................................................. 12
1.5 The role of integrase in virion morphogenesis ........................................................................ 14
1.6 Conclusions ............................................................................................................................. 17
References ..................................................................................................................................... 18

Chapter 2: HIV-1 integrase binding to the genomic RNA is mediated by electrostatic
interactions ................................................................................................................................... 32
2.1 Abstract ................................................................................................................................... 33
2.2 Importance .............................................................................................................................. 34
2.3 Introduction ............................................................................................................................ 35
2.4 Results ..................................................................................................................................... 37
2.4.1. Compensatory IN D256N/D270N substitutions emerge in the background of the IN
R269A/K273A class II mutant virus ...................................................................................................37
2.4.2 D256N/D270N substitutions restore IN-gRNA binding for the R269A/K273A class II IN
mutant viruses and lead to formation of correctly matured virions ....................................................40
2.4.3 Electrostatic interactions are required for IN-gRNA binding. ...................................................41
2.4.4 D256R substitution fully restores virion infectivity and RNA binding for a separate class II IN
(R262A/R263A) mutant ......................................................................................................................44
2.4.5 Effects of the compensatory mutations on functional oligomerization of IN and IN-RNA
interactions. .........................................................................................................................................47
2.4.6 Sensitivity to ALLINIs is determined by distinct residues within the CTD ..............................48
2.4.7 Characterization of IN mutations present in latently infected cells ...........................................51
2.5 Discussion ................................................................................................................................ 52
2.6 Materials and methods ............................................................................................................ 56
References ..................................................................................................................................... 63

Chapter 3: Studying the role of integrase and other RNA-binding proteins in the replication of
retroviruses ................................................................................................................................... 72
3.1 Introduction ............................................................................................................................ 73
3.2 Identifying the RNA targets of RNA binding proteins with CLIP .......................................... 74

ii

3.3 Integrase preferably binds to purine-rich sequences on viral RNA ........................................ 78
3.4 Conservation of integrase-RNA binding in retroviruses ......................................................... 81
3.5 Discussion ................................................................................................................................ 84
References ..................................................................................................................................... 85

Chapter 4: A simplified quantitative real-time PCR assay for monitoring SARS-CoV-2 growth
in cell culture................................................................................................................................ 90
4.1 Abstract ................................................................................................................................... 91
4.2 Importance .............................................................................................................................. 92
4.3 Observation ............................................................................................................................. 93
4.4 ACKNOWLEDGEMENTS ..................................................................................................... 97
Table S1. Sequences of the primers and probes used in this study ............................................. 102
Table S2. Sources and properties of the compounds used in this study. ..................................... 103
REFERENCES ........................................................................................................................... 104

Chapter 5: Summary and Future Studies ................................................................................. 107
5.1 Summary ............................................................................................................................... 108
4.2 Future Studies ....................................................................................................................... 111
Temporal assessment of IN-RNA interaction during virion morphogenesis ....................................................111
Isolation and structural characterization of integrase-RNA complexes ............................................................112

References ................................................................................................................................... 116

iii

List of Figures
Chapter 1
Figure 1: Overview of the HIV-1 life cycle ..............................................................................6
Figure 2: Structures of HIV-1 strand transfer complex intasomes (pdb code: 5U1C) .......9
Figure 3: Mechanism of retroviral integration .......................................................................10
Figure 4: HIV-1 virion morphologies.......................................................................................15
Chapter 2
Figure 1: D256N and D270N substitutions in HIV-1 IN suppresses the replication defect of
R269A/K273A class II IN mutant virus ...................................................................................39
Figure 2: D256N and D270N substitutions restore IN-gRNA binding and accurate virion
maturation for the R269A/K273A class II IN mutant virus ..................................................41
Figure 3: Restoring the net charge of IN-CTD restores RNA binding and infectivity for the
R269A/K273A class II mutant ..................................................................................................43
Figure 4: D256R and D256K substitutions restore IN-RNA binding and infectivity for the
HIV-1NL4-3 IN(R262A/R263A) virus .....................................................................................45
Figure 5: Electrostatic potential maps of HIV-1 IN bearing class II and compensatory
mutations ....................................................................................................................................46
Figure 6: Assessing multimerization properties of IN in mutant viruses .............................48
Figure 7: Secondary site suppressors of the IN R269A/K273A mutant increase
susceptibility to ALLINIs ..........................................................................................................50
Figure 8: Characterization of IN mutations present in latently infected CD4+ T-cells ......51
Chapter 3
Figure 1: Schematic diagram of steps involved in PAR-CLIP experiments ........................76
Figure 2: Purine-rich sequences are preferentially bound by IN ..........................................79
Figure 3: Purine-rich sequences are preferentially bound by IN. .........................................80
Figure 4: HIV-1 IN can bind to cellular RNAs in the absence of the genome......................81
Figure 5: Morphology of mature retrovirus virions ...............................................................82

iv

Figure 6: Autoradiographs (top) showing IN-RNA adducts and Western blots of IN
(bottom) in MLV, EIAV, MVV, and MMTV ..........................................................................83
Chapter 4
Figure 1: Development of a simplified Q-RT-PCR assay for SARS-CoV-2 viral RNA
detection in cell culture supernatants ......................................................................................99
Figure 2: A compound screen to validate SARS-CoV-2-specific inhibitors and entry
pathways .....................................................................................................................................100
Supplementary Figure 1: A screen to test the antiviral activities of various HIV-1-specific
inhibitors .....................................................................................................................................101

Chapter 5
Figure 1: Isolation of IN-RNA complexes................................................................................114

List of Tables

Supplementary Table 1: Sequences of the primers and probes used in this study ..............102
Supplementary table 2: Sources and properties of the compounds used in this study .......103

v

Acknowledgements
This page is dedicated to the many brilliant and generous scientists who inspired and supported
my scientific and academic growth, including Sebla Kutluay, Jenna Eschbach, Maritza PurayChavez, Kyle Vuong, Dana Lawson, Keanu Davis, Kasyap Tenneti, Shawn Mohammed,
Nakyung Lee, Mike Wang, Tung Dinh, Mamuka Kvaratskhelia, Robert Gifford, Alan Engelman,
Wen Li, Wandy Beatty, Sergej Djuranovic, Liang Shan, Megan Baldridge, Siyuan Ding, Sondra
and Milton Schlesinger, Stacy Kiel, Zhongsheng You, and Roberta Faccio.

I am particularly grateful to my advisor and mentor Dr. Sebla Kutluay. By her unwavering
support and encouragement, Dr. Kutluay has given the best opportunity and space to learn and
grow as a scientist. Without her mentorship, I would not have made it this far.

I also wish to acknowledge my family, friends, and classmates who have believed in me and
supported me during many up and downs. I am grateful for my teachers and professors who
encouraged my academic aspirations. Finally, I want to thank the DBBS program and
Washington university for providing some of the learning resources during my PhD training.

Christian Shema Mugisha
Washington University
May 2022

vi

ABSTRACT OF THE DISSERTATION
Molecular Characterization of Integrase-RNA interactions and their role in the replication of
HIV-1 and other retroviruses
by
Christian Shema Mugisha
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2022
Professor Sebla B. Kutluay, Chair

HIV-1 integrase (IN) enzyme has an emerging non-catalytic role in particle maturation, which
involves its binding to the viral genome in virions. Allosteric integrase inhibitors (ALLINIs) and
class II integrase substitutions inhibit the binding of IN to the viral genome and cause formation
of eccentric non-infectious HIV-1 particles. These viruses are characterized by the
mislocalization of the viral ribonucleoprotein complexes between the translucent conical CA
lattice and the viral lipid envelope. We have previously demonstrated that IN binding to the viral
genome is mediated by basic residues within the C-terminal domain of IN.

In the first chapter, we show how basic residues of the IN CTD mediate RNA binding.
We report that we have isolated secondary site suppressors of a class II IN mutant
(R269A/K273A) which directly inhibits IN binding to the viral genome. Full-genome deep
sequencing revealed the sequential emergence of D256N and D270N mutations within three
passages. Reintroduction of these substitutions nearly fully restored the replication defect of the
R269A/K273A virus, restored the ability of IN to bind RNA and led to the formation of particles
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with mature morphology. Furthermore, we found that D256R and D256R/270R substitutions
also increased the infectivity of R269A/K273A as well as R262A/R263A IN viruses. The nature
of these suppressor mutations suggests that IN-RNA binding is partly dictated electrostatic
interactions between IN CTD basic residues and RNA. Though these findings imply some level
of non-specificity towards gRNA binding, CLIP-seq and in-vitro binding experiments (reported
in the third chapter) revealed a striking preference of IN for binding to purine-rich sequences on
the viral genome. Taken together, our findings suggest that a combination of electrostatic
interactions and semi-specific binding to the viral genome underlies the non-catalytic role of IN
in virion maturation. Additional preliminary findings reported in the third chapter show that INRNA binding is a conserved property of retroviruses, further reaffirming this characteristic
would be an archetypical target for new antiretroviral agents.
In the fourth chapter, we report how we used our expertise of RNA viruses to create an
assay that has been usefully in screening for antiviral agents for the SARS-Cov-2 virus during
the COVID-19 pandemic.
Overall, this dissertation illustrates how the basic molecular properties of integrase and
viral genomic RNA that underlie their binding. Furthermore, it shows how these properties could
be potentially targeted by the next generation of antiretroviral agents.

viii

Chapter 1: Introduction
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1.1 Introduction
The human immunodeficiency virus type 1 (HIV-1), the causative agent of AIDS, has been one
of the deadliest viruses of the last four decades. As of 2018, there were about 37 million living
with HIV worldwide, and there were 1 million HIV-related deaths the same year (8). HIV1 is a
lentivirus that contains two copies of positive sense single-stranded genomic RNA (gRNA), 9 kb
in size (10). The viral gRNA forms a ribonucleoprotein (RNP) complex together with the
nucleocapsid protein (NC), and reverse transcriptase (RT) and integrase (IN) enzymes in virions
(11). The dense vRNP complex is encased within a conical lattice composed of ~2000 copies of
capsid (CA) protein, together forming the viral “core” . A defining feature of retroviruses is the
reverse transcription of the viral RNA genome (gRNA) and integration of the resultant linear
viral DNA into a host chromosome, which establishes lifelong infection. The integration reaction
is catalyzed by the viral integrase (IN) enzyme, which possesses 3’ processing and DNA strand
transfer activities . This catalytic role of integrase has been efficiently targeted by a group of
antiretroviral agents known as integrase strand-transfer inhibitors (INSTIs) (16, 17). Currently,
there are four FDA-approved INSTIs –raltegravir (18-20), elvitegravir , dolutegravir , and
bictegravir (18, 19, 21-23); they have become essential constituents anti-retroviral therapy
regimen because of their high potency and tolerance profiles . Even with the high efficacy of
INSTIs, mutations that confer resistance to several INSTIs have been observed in patients (24)
and treatment selects for the drug resistant viruses (24-27). These observations reiterate the need
for further research and development of novel antiretroviral therapies.
The integrase enzyme also has a non-catalytic function in HIV-1 virion morphogenesis .
IN binds to the viral genomic RNA (gRNA), and this binding is essential for proper positioning
of the gRNA within the capsid lattice during virion maturation. This second function of IN could
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be targeted by a new generation/class of antiretroviral agents, which would complement existing
regimens and increase the barrier to INSTI resistance. This introduction chapter briefly reviews
the HIV-1 life cycle while expanding on the roles IN’s functions in integration and virion
morphogenesis. A comprehensive mechanistic understanding of IN’s functions in the HIV-1 life
cycle would be pivotal to the development of novel and more efficient antiretroviral drugs.
1.2 Overview of the HIV-1 replication cycle
The human immunodeficiency virus type 1 (HIV-1) is a lentivirus that contains two copies of
positive sense single-stranded RNA, 9 kb size (31-33). In their mature form, HIV-1 virions have
a viral core consisting of a conical capsid (of about of ~2000 copies of capsid (CA) monomers)
which surrounds the vRNP complex composed of viral RNA, the nucleocapsid protein (NC),
integrase (IN), and reverse transcriptase (RT) (Figure 1). The viral core is surrounded by a lipid
bilayer envelope, derived from the host cell plasma membrane, traversed by glycoprotein spikes
(Env) that serve as receptors during viral entry (34). During viral entry, the HIV protein envelope
(Env) binds to the primary cellular receptor CD4 and then to a cellular coreceptor
(CXCR4/CCR5); these receptors are mostly on CD4+ T cells and monocyte/macrophage lineage
cells. Following the binding of Env to the cell receptors, the viral and cellular membranes fuse
and then the viral core is released into the cytoplasm (33).
Subsequent to viral entry, the viral core is then moved towards the nucleus as the RT
enzymes synthesizes the viral DNA (vDNA) from the HIV-1 RNA genome . While multiple
studies have previously concluded that the viral core uncoats during this stage , several new
studies have shown that the capsid lattice stays almost intact until it is imported into the nucleus .
After the synthesis of vDNA, the integrase enzyme, which stays associated with the RT complex,
forms multimers that engage both ends of the vDNA forming the intasome complex. In the cell
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nucleus, as part of the intasome complex, IN catalyzes the integration of viral DNA into the host
cell chromosome .
Viral gene expression from the integrated provirus depends on viral and cellular
transcription factors which lead to the transcription of single full-length viral mRNAs by the host
RNA polymerase II machinery (46-48). All HIV-1 mRNAs are generated from a single primary
polycistronic viral transcript that undergoes extensive alternative splicing . The completely
spliced 1.8kb mRNAs encode Tat, Rev and Nef regulatory proteins, they are shuttled to the
cytoplasm through the NXF1/NXT1nuclear export complex . The partially spliced 4 kb size class
encode Vif, Vpr, Env, Vpu and a truncated form of Tat. The unspliced primary transcript
encodes Gag and Gag-Pol proteins, and serves as genomic RNA that is packaged into progeny
virions . In contrast to Gag, Gag-Pol has a pol extension which codes for the viral enzymes
protease (PR), RT, and IN. Gag-Pol is produced as result of programmed ribosomal frame
shifting of the Gag ORF during translation of the unspliced viral RNA (52, 53). The export of the
partially spliced and unspliced viral RNA to the cytoplasm is Rev-dependent. Rev is translated in
the cytoplasm from the fully spliced HIV-1 mRNA. Rev is then translocated to the nucleus,
binds to the Rev-response-element present in partially and fully spliced viral RNA, and then
mediates their export through the CRM1 nuclear export complex (54, 55).

The viral envelope protein (Env) is synthesized at the endoplasmic reticulum, glycosylated, and
cleaved into gp120 and gp41 at the Golgi complex . Cytoplasmic assembly of virions is initiated
by interaction of NC, a domain of Gag and Gag-Pol, with the packaging signal in the unspliced
genomic RNA (58-60). The Gag and Gag-Pol proteins are then transported to the plasma
membrane, where the membrane-bound MA mediates oligomerization and assembly of Gag and
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Gag-Pol units. MA domain of Gag and Gag-Pol also associates with Env to initiate budding , the
virions released from cells are initially in an immature state where Gag and Gag-Pol are radially
arranged across the virion. Shortly after virion release, Gag and Gag-Pol polyproteins are
cleaved and modified by the viral PR enzyme. This results in the formation of mature infectious
virions that are spherical with a conical CA lattice that encloses the vRNP complex (Fig. 1),
forming the viral core .
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Figure 1: Overview of the HIV-1 life cycle
HIV-1 virions contain two copies of a single-stranded RNA (vRNA, in black) genome enclosed inside a
conical capsid lattice. After viral entry the viral core is released inside the cytoplasm and transported
towards the nucleus. The vRNA is reversed transcribed into double-stranded DNA (vDNA, in black.)
which is integrated into the host DNA. Following transcription of vDNA, the produced vRNA and viral
proteina assemble at the plasma membrane and bud of from the cell as immature virions. During virion
maturation, Gag and Gag-Pol are cleaved leading to formation of mature virions where the capsid lattice
reforms again around the viral ribonucleoproteins complex.
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1.3 HIV-1 Integrase and its catalytic Role
Similarly to other retroviruses, the lentivirus HIV-1 must integrate the DNA copy of its RNA
genome into the host cell chromosome; it is this step of the virus replication that helps maintain
lifelong infection in patients. The integration process is mediated by the HIV-1 integrase (IN)
enzyme. IN is a special recombinase that is incorporated into the virus particles as part of GagPol. Integration occurs within the context of a large nucleoprotein structure known as the
preintegration complex (PIC) . During integration, both ends of the linear vDNA are held
together by a multimer of IN catalyzes integration . The IN enzyme has three functionally
distinct domains; an N-terminal domain (NTD) that has conserved HCCH Zn2+-binding motif,
an RNase H-like catalytic core domain (CCD), and a C-terminal domain (CTD) which has been
shown to play a role in nucleic acid binding (67). While the NTD and CTD domains facilitate
DNA binding and formation of the intasome complex, the CCD possesses a conserved D,D,-35E motif essential for IN’s catalytic activity (70). Mutations at these conserved residues block the
catalytic activity of IN and thus virus replication (72), they are collectively known to as class I
IN mutations.
To perform its catalytic functions, IN multimerizes to different levels forming monomers,
dimers, and tetramers (75). Furthermore, there had been studies showing that small molecules
could allosterically block the catalytic function of IN by binding at the interface of IN dimers
within an IN tetramer, thus disrupting the proper multimerization of IN around vDNA into a
fully functional nucleoprotein complex (76). Even though the enzymatic functions of IN has
been studied since the 1980s, a complete understanding of its catalytic functions was only
recently discovered owing to the detailed high-resolution structure of IN-DNA complexes or
intasomes for the spumavirus prototype foamy virus (PFV) . Since then, intasome structures of
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the α-retrovirus Rous sarcoma virus (RSV) and β-retrovirus mouse mammary tumor virus
(MMTV) have been characterized . While the intasome structures of the spumavirus PFV are
primarily tetrameric, RSV and MMTV have octameric intasome structures revealing an
evolutionary diversity among retroviral intasomes (Figure 2) .
Resolving a detailed structure of the HIV-1 intasome has long been hindered by the
tendency of HIV-1 IN to aggregate in solution. A recent study overcame this hurdle by using
hyper-active HIV-1 IN mutant protein with improved solubility; using cryo-EM, it was shown
that HIV-1 intasomes form a range of oligomeric configurations from tetramers to higher order
dodecameric complexes for integration (84, 85) (Figure 2).
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Figure 2: Structures of HIV-1 strand transfer complex intasomes (pdb code: 5U1C)
(A) CryoEM reconstruction of the STC, segmented by IN protomer (red, green, yellow, blue) and product
DNA component (dark and light grey). (B) Atomic model, similarly, colored as in A. (C) segmented
cryoEM density and (D) asymmetric subunit of the atomic model colored by IN domain; NTD (green),
CCD (beige), NTD-CCD linker (cyan), CTD (purple).

Following the formation of the intasome complex, IN catalyzes integration through two
biochemically and temporally distinct biomolecular nucleophilic substitution reactions: 3’
processing and strand transfer (Figure 3) (86, 87). During the 3’ processing, IN catalyzes the
hydrolysis of a phosphodiester bond from each 3’ vDNA end which removes two to three
nucleotides; this step leaves reactive 3’ hydroxyl groups . These free 3’ hydroxyl groups act as
nucleophiles in the strand transfer reaction where they are covalently inserted into the major
groove of the host DNA in staggered fashion . This produces an integration intermediate with
9

unjoined 5’ vDNA overhangs (89, 90). Thereafter, the strand transfer complex (intasome)
dissembles and DNA polymerase, 5’ flap endonuclease, and DNA ligase enzymes respectively
fill in the single-stranded regions, excise 5’ vDNA overhangs, and join the vDNA 5’ ends to the
host DNA strands (21, 24, 91, 92). A characteristic consequence of retoroviral integration and
the subsequent gap repair is the generation of short target DNA duplications flanking the
integrated provirus. The size of these target site duplications varies between various retroviruses.
For example, while the 5 bp target site duplication is the hallmark of HIV-1, spumavirus
prototype foamy virus integration results in a 4bp target site duplication .

Figure 3: Mechanism of retroviral
integration
The integration process has two step-3’
processing and strand transfer- both
catalyzed by integrase. During 3’
processing, an IN dimer makes the
phosphodiester bonds at the site of vDNA
cleavage susceptible to nucleophilic attach
by water or other nucleophiles. This leads to
the removal of a dinucleotide from the 3’
ends of the viral DNA (red and brown) to
expose free 3’ hydroxyls. During strand
transfer, another IN dimer inserts the 3’ ends
of the viral DNA into the host DNA (black),
leaving gaps in the target DNA and the
loose 5’ ends of viral DNA. The gaps and
loose ends are subsequentially repaired by
host cell machinery.

HIV-1 strongly prefers integration within transcriptionally active units in the nuclear
periphery . These active transcription units are associated with regions of high G/C content, high
gene density, high CpG island, short introns, high frequencies of Alu repeats, low frequencies of
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LINE repeats, and characteristic epigenetic modifications . HIV takes advantage of different cell
factors to promote efficient integration and optimize the integration at favored sites. Most
notably, IN binds to the chromatin-associated cellular protein lens epithelium-derived growth
factor (LEDGF) through its CTD (76). The PWWP motif within the N-terminus of LEDGF binds
to the nucleosomes trimethylated at Lys36 of histone 3 (H3K36me3), one of the common
epigenetic markers for transcriptionally active sites (99). In fact, mapping of integration sites in
LEDGF/p75 knockdown cells showed that integration targeting to transcription sites was
significantly reduced; on the contrary, integration targeting to transcriptionally active sites was
rescued upon restoration of LEDGF/p75 expression (14, 24, 73, 75, 76). Imaging studies have
showed that LEDGF/p75 binds to condensed chromosomes at mitosis, and IN also colocalizes
with the chromatin in the presence of LEDGF/p75 . Altogether, the convention is a model where
LEDGF/p75 guides and tethers IN to chromatin at active transcription units.
Some of the most potent available antiretroviral therapies are integrase inhibitors known
as INSTIs (integrase strand transfer inhibitors). Four INSTIs are part of clinically regimes,
raltegravir , elvitegravir (96), dolutegravir (97), and bictegravir (98, 101). A fifth INSTI–
cabotegravir - is currently in late-stage clinical trials. INSTIs bind to the catalytic core domain
(CCD) of IN; this displaces the reactive 3’ end of the viral DNA thus preventing its insertion into
the host DNA (102). However, treatment with INSTIs can lead to selection of drug resistance
and resistance is often acquired through mutations within the CCD of IN. Although such
mutations can affect the fitness of the virus, it has been observed that compensatory mutations
that increase IN catalytic activity are found in patients on INSTIs.
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1.4 Virion Morphogenesis
The infectious virus particles (virions) of HIV-1 is spherical with a diameter of about 120 nm
with viral glycoproteins protruding from its envelope. Following the release of virions, they
undergo an interior morphology transformation, named maturation. The maturation process
changes the virion from an immature form where the Gag and Gag-Pol proteins are radially
arranged across the viral envelope in a donut-shaped particle to a mature virion particle lined
with viral matrix proteins (MA) containing a condensed conical core composed of capsid lattice
that encapsidates the vRNP complex (103). The maturation process is essential for the formation
infectious virions.
The assembly of HIV-1 virions is driven by the viral major sturctual protein, Gag. The
precursor proteins Gag (Pr55) and Gag-Pol (Pr160) are expressed from an unspliced full-length
viral RNA. The N-terminal myristoylation target Gag and Gag-Pol to the plasma membrane and
the adequate accumulation of precursor proteins leads to their assembly at the host cell
membrane (108). HIV-1 particle assembly is initiated when the nucleocapsid domain (NC) of
Gag binds with high specificity to a single dimer of viral genomic RNA (gRNA) (109, 110). NC
interacts with RNA through electrostatic binding with its positively charged residues and more
specifically via its zinc finger binding pockets that interact with unpaired guanosine residues .
HIV-1 RNAs are 5’ capped and 3’ polyadenylated, this makes HIV-1 RNA similar to the host
cell’s mRNA which is challenging for selective packaging of viral RNA during virion assembly.
However, the HIV-1 RNA contains a packaging sequence called psi (ψ) which is specifically
recognized by NC as mentioned above. The packaging sequence is formed by four stem loop
structures-SL1, SL2, SL3, and SL4; these structures allow viral RNA to dimerize, and they are
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part of the 5’ untranslated region (5’ UTR) (112). SL1 initiates the dimerization of viral RNA
molecules, which is crucial for selective packaging of two copies of full-length vRNA (113). The
dimer initiation site of SL1 contains a bulge of 9 bases; six of these bases form a palindrome
which leads to the formation of Watson-Crick base pairs with the second RNA molecule.
The main constituents of HIV-1 virions are Gag, Gag-Pol, Env, viral membrane lipids,
and the two copies of genomic RNA. In addition to these, the virion packages some viral
accessory proteins which are necessary at different stages of the virus replication. Gag molecules
have been shown to interact with various components of the intracellular vesicle trafficking
pathways-AP-1, AP-2, and AP-3 -and the cellular motor protein KIF4 (114). The myristoylation
of Gag, the basic patch on the MA domain, and the plasma membrane-specific lipid phosphatidyl
inositol (4,5) biphosphate (PI(4,5)P2) facilitate the targeting of Gag to the plasma membrane (24,
104, 118). The binding between the MA domain of Gag and PI(4,5)P2 exposes the aminoterminal myristoyl group enabling the stable anchoring of Gag on the inner leaflet of the cellular
membrane . Gag molecules arrive at the plasma membrane as small oligomers (dimers or
monomers) before polymerizing around nucleation sites composed of Gag-RNA complexes (21,
23, 91, 94, 95, 105, 108, 110, 119-124). Env is an integral membrane protein and is cotranslationally incorporated in the endoplasmic reticulum (ER) membranes. Env is delivered to
the plasma membrane through vesicular secretory pathways where it is glycosylated, assembled
into tetrameric complexes, and processed into the trans-membrane (gp41) and surface (gp120)
subunits by the cellular protease furin .
Through a complex combination of Gag–lipid, Gag–Gag, and Gag–RNA interactions, a
multimeric budding structure forms at the inner leaflet of the plasma membrane. The budding
virus particle is ultimately released from the cell surface in a process that is promoted by an
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interaction between the late domain in the p6 region of Gag and host proteins, most notably the
endosomal sorting factor, TSG101(tumor susceptibility gene 101) . The released virions are in
an immature state with 2000-4000 Gag molecules that are radially arranged along the inside of
the viral envelope in a donut shape; in this form, MA remains anchored to the membrane at one
end of Gag and NC still binds to vRNA . Following budding, PR enzyme cleaves Gag and GagPol at multiple sites in a defined sequence to generate mature proteins matrix (MA), capsid (CA),
nucleocapsid (NC), p6, two spacer peptides (SP1 and SP2) integrase (IN), reverse transcriptase
(RT), and PR . The cleavage of Gag and Gag-Pol triggers a structural rearrangement called
maturation, in which the immature virions become mature infectious virion characterized by an
electron dense, conical core. The core is made of 1000-1500 monomers of CA assembled in a
conical lattice around two single-stranded HIV-1 RNA molecules bound by the NC and
associated with IN and RT . This virion maturation process is essential for the released virus
particles to become infectious and initiate a new round of infection.
1.5 The role of integrase in virion morphogenesis
Integrase has long been known for its catalytic function of integrating the vDNA into the host
chromosome. Several decades ago, it was noticed that IN might have other non-catalytic
functions in virus replication based on observations from mutation analyses. Most notably, a
group of pleiotropic mutations known as class II mutations caused defects in virion assembly ,
morphogenesis , and reverse transcription . Most of the class II mutations did not affect the
catalytic activity of IN in vitro studies . A hallmark of class II IN mutant viruses is a phenotype
known as “eccentric morphology’, characterized by the mislocalization of the vRNP outside of
the conical capsid lattice (Figure 5). Deletion of IN causes similar morphological defects as
class II mutations (45, 55, 57, 123, 149-151).
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Interestingly, viruses produced from cells treated with allosteric integrase inhibitors
(ALLINIs) display eccentric morphology like that of class II mutations . ALLINIs have,
however, been designed to inhibit integration by blocking the binding of LEDGF/p75 to IN .
ALLINIs inhibit integration by competing with LEDGF for IN by engaging a V-shaped binding
pocket which is created by the catalytic core domains of two IN dimers in the intasome complex
(152) and by causing aberrant IN multimerization in a way that forms catalytically inactive
multimers that cannot form active intasomes (92, 93). The effect of ALLINIs and class II IN
mutations on virion morphology suggested that IN plays a crucial role in HIV-1 particle
morphogenesis. Although it had been shown that most class II mutations and ALLINIs interfered
with proper IN multimerization, the exact mechanism by which IN was involved in vRNA
encapsidation remained elusive in the retrovirology community for many years.

Figure 4: HIV-1 virion morphologies
Immature viral particles consist of 2000-4000 molecules of Gag and Gag-Pol radially arranged along the
inner leaflet of the viral membrane, the genomic vRNA is bound to Gag’s NC domain. In mature virions,
the vRNP (vRNA bound by NC and condensed with RT and IN) is enclosed in the conical capsid lattice
forming the viral core. In eccentric viral particles the vRNA is mislocalized outside of the capsid.

In 2016, a groundbreaking study from our lab and collaborators discovered that IN binds
to vRNA in mature virions, this binding is necessary for the proper encapsidation of vRNPs
inside the CA lattice after virion maturation (94) (Fig. 5). In these studies, the binding between
IN and gRNA was discovered using a method known as crosslinking immunoprecipitation that is
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coupled with next generation sequencing (CLIP-seq), a method which captures protein-RNA
complexes in physiological conditions (1). CLIP-seq revealed that IN binds to gRNA at discrete
sites that are different from other RNA-binding HIV-1 proteins such NC; in-vitro RNA-binding
assays revealed that IN had high affinity for structured RNA elements such as TAR (2). IN not
only binds RNA, but also modulates RNA structure in vitro by bridging multiple RNA molecules
together (3). Several basic residues of the IN CTD- K264, K266, and K273 - were shown to
directly bind to viral RNA, mutations in any of these residues blocked IN-gRNA binding (4, 5).
Later studies by Elliott et al revealed that class II IN mutations impeded IN-RNA binding
through three distinct means: 1) reducing packaged IN levels thus precluding formation of IN
complexes with viral RNA; 2) impairing functional IN multimerization hence disrupting INRNA binding; 3) directly impairing IN-RNA binding without adversely affecting IN levels or
functional IN multimerization . All class II mutations cause formation of morphologically
eccentric particles by blocking IN-gRNA binding; following viral infection, the viral genome of
such particles was degraded in target cells as a result of the mislocalization of the genomic RNA
outside of the protective capsid lattice . Similarly, IN-gRNA binding is blocked and eccentric
virions are formed when virions were produced from cells treated with ALLINIs .
Overall, IN-gRNA binding permits the encapsidation of the viral genomic RNA into the
protective capsid lattice. Class II IN mutations and ALLINIs block IN-gRNA binding causing
formation of virions with eccentric morphology, the resulting degradation of IN and gRNA in
target cells, as well as spatial separation of reverse transcriptase and gRNA during the early
stages of viral infection.
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1.6 Conclusions
The HIV-1 integrase (IN) is a multifunctional enzyme that plays key roles during the integration
and virion maturation steps of the virus replication. During integration, IN engages viral and host
DNA catalyzing the incorporation of viral DNA into the host chromosome, this is the step that
establishes life-long infection in HIV-1 patients. During virion morphogenesis, IN multimers
bind to gRNA giving it a nucleation point and allowing it to be packaged inside the protective
capsid lattice. Class II mutations and allosteric integrase inhibitors (IN) block IN-gRNA binding,
thus leading to formation of non-infectious virions with an eccentric morphology where the
gRNA is mislocalized outside of the capsid lattice.
IN presents itself as a great target for developing new antiretroviral therapies because
both its functions in integration and virion maturation are essential for HIV-1 replication. The
catalytic activity of IN has been successfully targeted by IN strand-transfer inhibitors (INSTIs)
which are a key component of anti-retroviral therapy regimens today. The discovery of INSTIresistant in clinics has raised concerns and it necessitates the development of novel IN-targeting
therapies. The secondary function of IN in virion maturations is a great target for developing
anti-HIV agents; however, there is still much to be understood about IN-RNA binding and it
regulates virion maturation. There are several ongoing studies on ALLINIs and how they can be
developed into efficient anti-retroviral therapies. Clear understanding of IN-RNA binding and
virion maturation will inform the development of new and improved integrase-targeting
antiretroviral therapies.
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2.1 Abstract
Independent of its catalytic activity, HIV-1 integrase (IN) enzyme regulates proper particle
maturation by binding to and packaging the viral RNA genome (gRNA) inside the mature capsid
lattice. Allosteric integrase inhibitors (ALLINIs) and class II IN substitutions inhibit the binding
of IN to the gRNA and cause the formation of non-infectious virions characterized by
mislocalization of the viral ribonucleoprotein complexes between the translucent conical capsid
lattice and the viral lipid envelope. To gain insight into the molecular nature of IN-gRNA
interactions, we have isolated compensatory substitutions in the background of a class II IN
(R269A/K273A) variant that directly inhibits IN binding to the gRNA. We found that additional
D256N and D270N substitutions in the C-terminal domain (CTD) of IN restored its ability to
bind gRNA and led to the formation of infectious particles with correctly matured morphology.
Furthermore, reinstating the overall positive electrostatic potential of the CTD through individual
D256R or D256K substitutions was sufficient to restore IN-RNA binding and infectivity for the
R269A/K273A as well as the R262A/R263A class II IN mutants. The compensatory mutations
did not impact functional IN oligomerization, suggesting that they directly contributed to IN
binding to the gRNA. Interestingly, HIV-1 IN R269A/K273A, but not IN R262A/R263A,
bearing compensatory mutations was more sensitive to ALLINIs providing key genetic evidence
that specific IN residues required for RNA binding also influence ALLINI activity. Structural
modeling provided further insight into the molecular nature of IN-gRNA interactions and
ALLINI mechanism of action. Taken together, our findings highlight an essential role of INgRNA interactions for proper virion maturation and reveal the importance of electrostatic
interactions between the IN CTD and the gRNA.
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2.2 Importance
HIV-1 integrase (IN) binds to the viral RNA genome through basic residues present within its Cterminal domain (CTD) and regulates proper virion maturation. Inhibition of IN binding to the
HIV-1 genome through mutations of CTD basic residues results in non-infectious particles in
which the viral genomes are mislocalized in virions. Here we isolated suppressor mutations that
restored the ability to bind RNA to an IN-CTD mutant lacking two basic residues. We found that
mutation of nearby acidic residues (i.e. D256 and D270) and restoring the overall charge of the
CTD can restore RNA binding, particle maturation and virion infectivity, but sensitize the
viruses to the inhibitory action of allosteric integrase inhibitors (ALLINIs) that target IN-RNA
interactions. Taken together, our findings highlight the electrostatic nature of IN-RNA
interactions mediated by the IN CTD and the gRNA phosphate backbone and provide key
genetic evidence that the ALLINIs engage the CTD of IN.
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2.3 Introduction
A defining feature of retroviruses is the reverse transcription of the viral RNA genome (gRNA)
and integration of the resultant linear viral DNA into a host chromosome, which establishes
lifelong infection. The latter reaction is mediated by the viral integrase (IN) enzyme, which
catalyzes 3’ processing and DNA strand transfer reactions . The catalytic activity of HIV-1 IN
has been successfully targeted by several integrase strand-transfer inhibitors (INSTIs) that have
become key components of frontline anti-retroviral therapy regimens due to their high efficacy
and tolerance profiles . In addition, HIV-1 IN has an emerging non-catalytic function in virus
replication (4, 17). Successful targeting of this second function can complement the existing
antiviral regimens and substantially increase the barrier to INSTI resistance.
HIV-1 IN consists of three independently folded protein domains: the N-terminal domain (NTD)
bears the conserved His and Cys residues (HHCC motif) that coordinate Zn2+ binding for 3-helix
bundle formation; the catalytic core domain (CCD) adopts an RNase H fold and harbors the
enzyme active site composed of an invariant DDE motif, and C-terminal domain (CTD) which
adopts an SH3 fold . Integration is facilitated by a cellular co-factor, lens epithelium-derived
growth factor (LEDGF/p75), which binds tightly to a site within the CCD dimer interface and
guides the preintegration complex to actively transcribed regions of the host chromosome . A
group of pleotropic IN substitutions distributed throughout IN, collectively known as class II
mutations, disrupt viral assembly , morphogenesis and reverse transcription in target cells often
without obstructing the catalytic activity of IN in vitro . A hallmark of class II IN mutant viruses
is the mislocalization of the viral ribonucleoprotein complexes (vRNP) outside of the viral capsid
(CA) lattice, a deformation which is often referred to as eccentric morphology . Although
originally designed to inhibit integration through preventing the binding of IN to LEDGF/p75 ,
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allosteric integrase inhibitors (ALLINIs) potently inhibit proper virion maturation (60) and lead
to the formation of virions that display a similar eccentric morphology observed with class II IN
mutations .
We have recently shown that binding of IN to the gRNA in mature virions accounts for the noncatalytic function of IN in virus replication and is required for proper encapsidation of the viral
ribonucleoproteins (vRNPs) inside the mature CA lattice (63-65). Class II IN substitutions and
ALLINIs block IN-gRNA binding, thus causing formation of virions with an eccentric
morphology . IN binds to multiple distinct locations on the gRNA, including the TAR hairpin
present within the 5’ and 3’UTRs of the gRNA and constitutes a high affinity binding site (63,
64, 66). IN preferentially binds to the gRNA in a tetrameric state, and many class II IN mutations
block IN-gRNA binding by disrupting the functional oligomerization of IN . Mutation of basic
residues within IN-CTD (i.e. R262, R263, R269 and K273) inhibits IN-gRNA binding without
altering functional IN oligomerization in virions and in vitro , suggesting that these residues are
directly involved in binding to the gRNA. On the other hand, the precise mechanism of how
these residues mediate recognition of specific sequence elements on the gRNA remains
unknown. For example, it is possible that the positively charged Lys and Arg residues interact
with the negatively charged RNA phosphate backbone in a non-specific or semi-specific manner,
depending on the folding and structure of the cognate RNA element, driven by electrostatic
interactions . Alternatively, these residues can mediate specific interactions with RNA targets
through H-bonding and van der Waals contacts with individual nucleobases .
To gain insight into the mode of IN-gRNA interactions, the non-infectious IN R269A/K273A
class II mutant virus was serially passaged in T-cells until the acquisition of compensatory
mutations. We found that two compensatory mutations, D256N and D270N, within the IN-CTD
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restored virion infectivity, IN-RNA interactions and accurate virion morphogenesis. As the D-toN mutations resulted in loss of two negative charges, possibly overcoming the loss of two
positive charges with the R269A/K273A class II substitutions, we tested whether restoring the
overall charge of CTD through other mutations would restore IN-gRNA binding and virion
infectivity. Indeed, the D256R substitution alone restored virion infectivity and RNA binding for
the IN R269A/K273A mutant. We further extended these findings to another class II mutant,
R262A/R263A, which was similarly suppressed by the D256R as well as D256K substitutions.
Compensatory mutations did not affect the ability of IN to multimerize in vitro or in virions,
suggesting that they restored the RNA-binding ability of IN directly. Interestingly, the IN
R269A/K273A, but not the IN R262A/R263A, mutant viruses bearing the compensatory
mutations had increased sensitivity to ALLINIs, providing key genetic evidence that specific
residues within the CTD, which are required for RNA binding, also contribute to ALLINI
mechanism of action. Together, our findings strongly suggest that IN-RNA interactions are at
least in part driven by electrostatic interactions between the basic residues within IN-CTD and
phosphate backbone of the gRNA and highlight that ALLINIs engage CTD residues to inhibit
RNA binding.

2.4 Results
2.4.1. Compensatory IN D256N/D270N substitutions emerge in the background of the IN
R269A/K273A class II mutant virus
The R269A/K273A class II IN substitutions obstruct IN-gRNA binding directly without interfering
with IN multimerization and result in the formation of particles with eccentric morphology (73). To
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better understand the molecular basis of how R269 and K273 residues mediate IN-gRNA binding,
viruses bearing the IN R269A/K273A mutations were serially passaged in MT-4 cells until the
emergence of compensatory mutations at the end of passage 3, which completely restored virion
infectivity (Fig. 1A). Deep sequencing of full-length gRNA isolated from virions across the three
passages revealed that viruses retained the IN R269A/K273A substitutions while sequentially
acquiring D256N and D270N mutations in IN (Fig. 1B). The D256N substitution emerged at the
end of passage 1 whereas the D270N mutation emerged later in passage 2 (Fig. 1B). Both
mutations were fixed by the end of passage 2 and no other mutations were observed elsewhere
on the viral genome.
The IN D256N and D270N mutations were introduced into the replication-competent pNL4-3
molecular clone bearing WT or R269A/K273A IN. Introduction of D256N and D270N substitutions
in IN had no observable effect on Gag (Pr55) expression or processing in cells or particle release
(Fig. 1C). Introduction of D256N and D270N mutations either individually or together (D2N) on
the WT IN backbone did not affect viral titers (Fig. 1D). Remarkably, while the individual D256N
and D270N mutations in the R269A/K273A IN backbone increased virus titers by 5-10-fold, the
D2N substitutions increased virus titers by 100-fold (Fig. 1D). Overall, these results demonstrate
that the combination of D256N and D270N mutations are sufficient to restore the replication
competency of the R269A/K273A class II IN mutant virus.
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Figure 1. D256N and D270N substitutions in HIV-1 IN suppresses the replication defect of
R269A/K273A class II IN mutant virus. (A) MT4-LTR-GFP cells were infected with equal particle
numbers of either WT or R269A/K273A IN mutant HIV-1 (NL4-3). The R269A/K273A IN viruses
were serially passaged for three times until the emergence of compensatory mutations. The graphs
represent the percentage of GFP positive cells as assessed by FACS over three passages at the
indicated days post-infection (dpi). (B) HIV-1 genomic RNA was isolated from viruses collected from
cell culture supernatants over the three passages (i.e. P1, P2, P3) and at the indicated days postinfection (i.e. D29, D40, etc.). Whole-genome deep sequencing revealed the acquisition of D256N
and D270N compensatory mutations. Heatmap shows the percentage of mutations at the indicated
passages and days post-infection (dpi). (C) HEK293T cells were transfected with full-length pNL43 expression plasmids carrying the D256N, D270N and D256N/D270N (D2N) IN mutations
introduced on the WT IN and IN R269A/K273A backbones. Cell lysates and virions were purified
two days post transfection and analyzed by immunoblotting for CA and IN. The image is
representative of five independent experiments. (D) HEK293T cells were transfected as in C and cell
culture supernatants containing viruses were titered on TZM-bl indicator cells. The titers are presented
relative to WT (set to 1). The columns represent the average of five independent experiments and the
error bars represent SEM (****p<0.0001, by one-way ANOVA with Dunnett’s multiple comparison
test).
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2.4.2 D256N/D270N substitutions restore IN-gRNA binding for the R269A/K273A class II
IN mutant viruses and lead to formation of correctly matured virions
We next assessed whether D256N and D270N substitutions rendered the R269A/K273A class II
IN mutant virus replication competent by restoring IN-gRNA binding and proper virion
maturation. To this end, IN-gRNA complexes were immunoprecipitated from UV-crosslinked
virions and visualized per CLIP protocol as described previously (75). Equivalent amounts of
immunoprecipitated IN from WT and R269A/K273A IN viruses, or those additionally bearing
the IN D256N and D270N substitutions, were analyzed for their ability to bind RNA. IN-RNA
complexes were readily visible for WT viruses as well as D256N, D270N and D2N mutants
(introduced on the WT backbone), but not from the R269A/K273A class II IN mutant viruses
(Fig. 2A). Introduction of the D256N substitution on R269A/K273A IN backbone modestly
enhanced the ability of IN to bind RNA, whereas the D270N substitution had no observable
impact (Fig. 2A). In contrast, the D2N substitution substantially enhanced the ability of
R269A/K273A IN to bind RNA (Fig. 2A). The virion morphology of WT and IN mutant viruses
was assessed by transmission electron microscopy (TEM). As expected, more than 80% of WT
particles had an electron-dense condensate that represents vRNPs inside the CA lattice, whereas
the majority of R269A/K273A class II IN mutant virions (~68%) had a clear eccentric
morphology (Fig. 2B). Consistent with effects on virus titers and RNA-binding, the introduction
of D256N/D270N substitutions restored the ability of the R269A/K273A IN mutant to form
properly mature virions (Fig. 2B). Cumulatively, these data show that D256N and D270N IN
substitutions restore infectivity for the R269A/K273A class II IN mutant virus through
reestablishing RNA binding and subsequently accurate virion maturation.
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Figure 2. D256N and D270N substitutions restore IN-gRNA binding and accurate virion
maturation for the R269A/K273A class II IN mutant virus. (A) Autoradiogram of IN-RNA
adducts immunoprecipitated from virions bearing the indicated substitutions in IN. Immunoblots
below show the amount of IP’ed IN or CA protein in lysates. Data shown are representative of at
least three independent experiments. (B) Examination of virion maturation in WT and mutant IN
viruses by thin section electron microscopy (TEM). The graph quantifies virion morphologies; each
column is the average of two independent experiments and error bars represent the SEM
(****p<0.0001, by repeated measures one-way ANOVA).

2.4.3 Electrostatic interactions are required for IN-gRNA binding.
IN-CTD is decorated with several acidic and basic amino acids resulting in a net charge of +3 (Fig.
3A). The D2N substitutions in effect restored the overall charge of the IN R269A/K273A CTD,
suggesting that the net electrostatic charge of the IN-CTD may be a key parameter in gRNA
binding. To test this hypothesis, we investigated whether restoring the overall charge of IN-CTD
through other mutations would also restore RNA binding and infectivity for the R269A/K273A
IN virus. We focused our analysis on D256 and D270 residues for the following reasons: i) these
amino acids were amenable to substitutions during virus passaging experiments; ii) D256N and
D270N substitutions in the context of WT HIV-1 yielded infectious virions, suggesting that these
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compensatory mutations do not significantly contribute to the catalytic activity of IN thus allowing
us to specifically probe their roles for IN-RNA interactions and virion maturation. To extend these
studies we introduced D256R, D270R and D256R/D270R (D2R) substitutions into the HIV-1NL4-3
IN R269A/K273A

backbone and transfected HEK293T cells with the resulting plasmids. Cell lysates and

cell-free virions were then analyzed for Gag processing, particle release, and infectivity. Overall,
D-to-R substitutions had no major effect on Gag (Pr55) expression or processing in cells (Fig. 3B).
Remarkably, the D256R substitution alone increased the titers of the R269A/K273A class II IN
mutant virus by 100-fold and to a level comparable to that of WT viruses (Fig. 3C). In contrast,
D270R substitution only had a modest impact on virus titers and the D2R substitution increased
virion infectivity at a modestly lower level than that of D256R and D2N (Fig. 3C). Importantly,
the D256R and the D2R substitutions completely restored IN-gRNA binding (Fig. 3D),
demonstrating that the increase in viral titers with the D256R and D2R substitutions correlates
well with enhancement of IN-gRNA binding. Further assessment of these substitutions with VprIN transcomplementation assays revealed that none of the IN substitutions impacted the catalytic
activity of IN, except for the D2R substitution (Fig. 3E), suggesting that the inability of the D270R
mutation to restore infectivity may be due to its adverse effects on the catalytic activity of IN.
Taken together, these findings indicate that restoring the overall charge of IN-CTD through D256R
mutation reestablishes virion infectivity and RNA binding for the IN R269A/K273A class II
mutant.
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Figure 3. Restoring the net charge of IN-CTD restores RNA binding and infectivity for the R269A/K273A
class II mutant. (A) Schematic diagram of IN and sequence of CTD residues with basic and acidic amino acids
highlighted in blue and red, respectively. (B, C) HEK293T cells were transfected with full-length proviral HIV1NL4-3 expression plasmids carrying pol mutations encoding for the indicated IN substitutions. (B) Cell lysates
and purified virions were harvested two days post transfection and analyzed by immunoblotting for CA and IN.
Representative image of one of five independent experiments is shown. (C) Infectious titers of WT or IN mutant
HIV-1NL4-3 viruses in cell culture supernatants were determined on TZM-bl indicator cells and normalized
relative to particle number based on RT activity. Titer values are expressed relative to WT (set to 1). The columns
represent the average of four independent experiments and the error bars represent SEM (****p<0.0001, by oneway ANOVA with Dunnett’s multiple comparison test). (D) Autoradiogram of IN-RNA adducts IP’ed from WT
or IN mutant HIV-1NL4-3 virions. The amount of immunoprecipitated IN protein was assessed by the immunoblot
below. Results are representative of four independent replicates. (E) A representative growth curve of HIV-1
NL4-3 IN (D116N) viruses that were trans-complemented with the indicated Vpr-IN mutant proteins in cell culture. Yaxis indicates fold increase in virion yield over day 0 as measured by RT activity in culture supernatants. Error
bars show SEM from 3 independent many replicates.
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2.4.4 D256R substitution fully restores virion infectivity and RNA binding for a separate
class II IN (R262A/R263A) mutant
We have previously shown that mutation of other basic residues within the IN-CTD (i.e.
R262A/R263A) also directly inhibit IN-gRNA binding without compromising functional
oligomerization of IN (78). We next wanted to extend our observations and test how substitutions
of D256 and D270 residues affect IN-gRNA binding and infectivity in the background of the IN
R262A/R263A mutant virus. Introducing the D256N, D270N and D2N compensatory mutations
on the IN R262A/R263A backbone did not affect Gag expression, processing, and virion release
(Fig. 4A). While the D256N substitution increased virion infectivity by 10-fold, the D270N
substitution had no impact and the D2N substitution had an intermediate phenotype (Fig. 4B),
demonstrating the context dependency of these compensatory mutations. The D256K and D256R
substitutions introduced in the R262A/R263A IN backbone also had minimal effects on Gag
expression, processing, and virion release (Fig. 4C). In contrast, the D256K substitution increased
viral titers at a greater degree than D256N and the D256R substitution completely restored virion
infectivity (Fig. 4D). In line with the titer data, D256K significantly increased RNA binding
whereas the D256R completely restored it in the context of the IN R262A/R263A mutant virus
(Fig 4E). D256N, D256K and D256R IN successfully transcomplemented a class I IN mutant,
suggesting that they did not distort the catalytic activity of IN (Fig 4F). Taken together, these
findings indicate that restoring the overall positive charge of IN-CTD through D256R or D256K
mutations is sufficient to restore virion infectivity and RNA binding to class II IN mutants that
directly inhibit RNA binding.
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Figure 4. D256R and D256K substitutions restore IN-RNA binding and infectivity for the HIV-1 NL43 IN(R262A/R263A) virus. (A-E) HEK293T cells were transfected with proviral HIV-1NL4-3 expression plasmids
carrying pol mutations for the indicated IN substitutions. (A, C) Cell lysates and virions were purified two
days post transfection and analyzed by immunoblotting for CA and IN. (B, D) WT or IN mutant HIV-1NL43 viruses in cell culture supernatants were titered on TZM-bl indicator cells. The titer values are presented
relative to WT (set to 1). The columns represent the average of two-three independent experiments, and
the error bars represent SEM (****p<0.0001, by one-way ANOVA with Dunnett’s multiple comparisons).
(E) Autoradiogram of IN-RNA adducts immunoprecipitated from WT or IN mutant HIV-1 NL4-3 virions.
The amount of immunoprecipitated IN was assessed by the immunoblot shown below. Immunoblots and
CLIP autoradiographs are representative of four independent replicates. (F) A representative growth curve
of HIV-1 NL4-3 IN (D116N) viruses that were trans-complemented with the indicated IN mutant proteins in cell
culture. Y-axis indicates fold increase in virion yield over day 0 as measured by RT activity in culture
supernatants. Error bars show SEM from 3 independent many replicates.

We next used reported X-ray structure and molecular modelling to visualize how class II and
compensatory IN mutations affect electrostatic potential of the CTD surface. Mutation of R269
and K273 residues expectedly resulted in a substantial loss of a basic patch in IN (Fig. 5A, B).
Both the D256R and D256N substitutions resulted in more positively charged surface distal from
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the R269/K273A residues (Fig. 5C, D), suggesting that compensatory mutations likely created an
additional interacting interface with gRNA binding. A similar outcome was observed when class
II R262A/R263A and compensatory D256R changes were introduced in the CTD (Fig. 5E-G).
While the D256R change is substantially distanced from R262/R263 and R269/K273 residues, we
note the following. R262, R263, R269, and K273 are positioned within the same highly flexible
C-terminal tail (aa 261-275), whereas D256 belongs to another, shorter (aa 252-257) loop (Fig.
5H). The highly pliable nature of the tail and the loop could be crucial for IN to optimally engage
with cognate RNA as well as allow for emergence of compensatory mutations at alternative sites
positioned in these IN segments.

Figure 5. Electrostatic potential maps of HIV-1 IN bearing class II and compensatory mutations.
(A-G) Electrostatic potential maps of the indicated HIV-1 IN mutants derived from the crystal structure
of Gupta et al. is depicted. Calculation results are displayed as an electrostatic potential molecular
surface. The low, mid, and high range values are -5, 0, and 5, respectively. (H) A cartoon view of the
CTD structure is shown with the C-terminal tail (aa 261-275) and the loop (aa 252-257) colored in cyan
and orange, respectively. Side chains of indicated residues are shown.
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2.4.5 Effects of the compensatory mutations on functional oligomerization of IN and INRNA interactions.
As functional IN oligomerization is a prerequisite for RNA binding (13), we next examined how
the compensatory substitutions affected IN oligomerization. For in virion analysis, purified HIV1NL4-3 virions were treated with ethylene glycol bis (succinimidyl succinate) (EGS) to covalently
crosslink IN in situ and virus lysates were analyzed by immunoblotting. As in WT virions, IN
species that migrated at molecular weights consistent with those of monomers, dimers, trimers,
and tetramers were readily distinguished in R269A/K273A or R262A/R263A viruses with
additional compensatory mutations (D256N/D270N, D256R, D256K, and D256R/D270R) but not
with the canonical class II IN mutant V165A that is unable to form functional oligomers (Fig 6AC). Complementary in vitro assessment of purified recombinant IN proteins by size exclusion
chromatography (SEC) revealed that D2N and D256R substitutions in the background of
R269A/K273A or the R262A/R263A class II mutants did not impact functional IN tetramerization
(Fig. 6D-H).
We have previously shown that recombinant IN binds to TAR RNA with high affinity and provides
a nucleation point to bridge and condense RNA (43). We next examined the ability of class II
mutant INs bearing compensatory mutations to bind and bridge TAR RNA. Consistent with
findings from CLIP, the D2N and D256R substitutions also enhanced or restored the ability of
R269A/K273 and R262A/R263A mutants to bridge between RNA molecules (Fig. 6I). Together,
these data demonstrate that the compensatory mutations directly restore the ability of IN to bind
RNA without altering functional IN oligomerization.
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Figure 6. Assessing multimerization properties of IN in mutant viruses. (A) Purified WT or IN
mutant HIV-1 NL4-3 virions were treated with 1 mM EGS, and virus lysates analyzed by immunoblotting
using antibodies against IN following separation on 6% Tris-acetate gels. The position of monomers
(M), dimers (D), and tetramers (T) are indicated by arrows in a representative western blot. (B,C)
Quantification of IN multimerization in virions from experiments conducted as in A. Error bars show
the SEM from three independent experiments. (D-I) Biochemical analysis of IN mutants
multimerization and their interactions with HIV-1 TAR RNA. (D-H) Representative SEC traces for
indicated recombinant IN proteins. The X-axis indicates elution volume (mL) and Y-axis indicates the
intensity of absorbance (mAU). Tetramers (T), dimers (D), and monomers (M) are indicated. (I)
Summary of mutant INs bridging TAR RNA compared to WT IN. Alpha screen counts at 320 nM for
each protein is shown. The graphs show average values of three independent experiments and the error
bars indicate standard deviation.

2.4.6 Sensitivity to ALLINIs is determined by distinct residues within the CTD
ALLINIs potently disrupt proper virion maturation through inducing aberrant IN multimerization
and consequently inhibiting IN-gRNA binding (43, 52). Recent structural studies have shown that
the ALLINI, GSK-1264, can directly engage residues within the IN-CTD through its tert-butoxy
and carboxylic acid moieties and induce open polymers (53). These findings are in line with
previous biochemical and modeling studies that also showed the involvement of the IN-CTD, in
particular residues K264 and K266, in ALLINI-induced aberrant IN multimerization (43, 79-81).
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Based on these prior findings, we wanted to test how adjacently positioned IN R262A/R263A and
R269A/K273A substitutions and the compensatory mutations affected ALLINI activities.
To this end, we examined effects of representative quinoline-based ALLINIs, BI-D or BI-B2, on
the viruses bearing the class II and compensatory mutations. While the titers of WT viruses only
decreased at ALLINI concentrations greater than 1 µM, the titers of IN R269A/K273A viruses
bearing D2N, D256R and D2R substitutions were significantly reduced by ALLINIs at
concentrations as low as 0.1 µM (Fig. 7A, B). In contrast, viruses bearing the
R262A/R263A/D256R IN were less sensitive to low concentrations of ALLINIs (Fig. 7D, E),
suggesting that the R269A and/or K273A mutations underlie the increased sensitivity to ALLINIs.
The increased sensitivity to ALLINIs correlated well with inhibition of RNA binding. While 0.1
µM of the ALLINI, BI-D, did affect the level of IN-gRNA binding in WT viruses, it significantly
reduced IN-gRNA binding in viruses with class II compensatory mutations on the R269A/K273A
but not R262A/R263A backbone (Fig. 7C,F). Taken together, our findings provide key genetic
and virological evidence that specific CTD residues required for RNA binding are also crucial for
the ALLINI mechanism of action.
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Figure 7. Secondary site suppressors of the IN R269A/K273A mutant increase susceptibility to
ALLINIs. (A, B, D, E) Titers of viruses bearing the indicated substitutions in IN produced from
HEK293T cells at different concentrations of ALLINIs, BI-B2 or BI-D. WT or IN mutant HIV-1NL4-3 in
cell culture supernatants were titered on TZM-bl indicator cells. The titer values are represented relative
to the mock control of each mutant (set to 1). Data are from two independent biological replicates. (C,
F) Autoradiogram of IN-RNA adducts immunoprecipitated from WT or IN mutant HIV-1 NL4-3 virions
produced from HEK293T cells in the presence of 0.1µM of BI-D. The amount of immunoprecipitated IN
protein was visualized by the immunoblot shown below. Immunoblots and CLIP autoradiographs results
are a representative of three independent replicates. (G) The GSK-1264 binding pocket between CCDCCD (brown) and CTD (light blue) from different IN subunits is shown (3) (PDB ID: 5HOT). GSK-1264
is in green with nitrogen and oxygen atoms colored blue and red, respectively. The side chain of R269 is
shown with nitrogen atoms colored in dark blue. Interactions between CTD R269 and CCD Q168 are
indicated by dashed lines.
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Figure 8. Characterization of IN mutations present in latently infected CD4+ T-cells. (A)
Alignment from Gifford- (B) HEK293T cells were transfected with proviral HIV-1 NL4-3 expression
plasmids carrying the R224Q, S230N, E246K, and G272R IN mutations. Cell lysates and virions were
purified two days post transfection and analyzed by immunoblotting for CA and IN. The image is
representative of two independent experiments. (C) WT or IN mutant HIV-1L4-3 viruses in cell culture
supernatants were titered on TZM-bl indicator cells. The titers are presented relative to WT (set to 1).
The columns represent the average of three independent experiments and the error bars represent SEM
(****p<0.0001, by one-way ANOVA with Dunnett’s multiple comparison test). (D) Autoradiogram of
IN-RNA adducts immunoprecipitated from virions bearing the indicated substitutions in IN.
Immunoblots below show the amount of immunoprecipitated IN.

2.4.7 Characterization of IN mutations present in latently infected cells
Persistence of HIV-1 in memory CD4+ T-cells as latent proviruses constitutes a major barrier to
HIV-1 cure. Although the majority of HIV-1 proviruses in these cells are defective , recent
evidence suggests that defective proviruses can be transcribed into RNAs that are spliced,
translated and can be recognized by HIV-1-specific cytotoxic T lymphocytes . We decided to
characterize IN mutations isolated from latently infected cells, given the possibility that class II
IN mutations existing in latently infected cells can result in the formation of defective particles
that may subsequently modulate immune responses. Though relatively uncommon, we found the
presence of R224Q, S230N, E246K and G272R substitutions in IN-CTD (Fig. 8A). Of note, only
the R224Q substitution resulted in loss of a positive charge, whereas the E246K and G273R
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substitutions resulted in gain of positive charge. These mutations were introduced into the NL4-3
proviral backbone with minimal effects on Gag expression and particle release (Fig. 8B). Although
the E246K virus was significantly less infectious (Fig. 8C), we did not find any evidence for
inhibition of IN-gRNA binding (Fig. 8D), suggesting that this mutant likely displays a class I
phenotype. Thus, we conclude that the class II mutant viruses are rarely present in the latently
infected cells and therefore unlikely to contribute to chronic immune activation.
2.5 Discussion
Class II IN mutations impair virion particle maturation by blocking IN-gRNA binding in virions
and those within the CTD, including R269A/K273A and R262A/R263A, impede IN-gRNA
binding without affecting functional oligomerization of IN . During serial passaging experiments
to identify compensatory mutations of the R269A/K273A class II IN mutant, viruses acquired
D256N and D270N IN mutations sequentially. We initially anticipated that mutations outside of
IN, such as CA and NC, could also arise, given that the IN R269A/K273A mutant is still
catalytically active and a compensatory mutation in CA or NC could presumably allow the proper
packaging of the gRNA within virions. On the other hand, we did not observe any such
substitutions showcasing the distinct role of IN:gRNA binding in proper virion maturation.
Notably, D256N and D270N substitutions each arose through a single mutation (D256N:
GACàAAC, D270N:GAUàAAU ) and thus likely provided an easier pathway for suppression
than reverting back to R269 and K273, each of which would require two mutations. Though other
mutations in IN could in principle restore the ability of IN to bind RNA, rise of such mutations
was likely constrained in part by the necessity to maintain a catalytically active IN.
IN CTD has a net positive charge of +3. While R269A/K273A class II mutations reduced the net
charge to +1, the introduction of D2N substitutions restored the overall charge back to a +3. This
52

observation suggested that the net electrostatic charge of the IN-CTD may be a key parameter for
IN-gRNA binding. Consistent with this hypothesis, the charge reversal by the D256R substitution
was sufficient to restore IN-gRNA binding for the R269A/K273A IN mutant. Though these
findings point to an electrostatic component of IN-RNA interactions, we cannot exclude the
possibility that the Asn and Arg residues also mediate H-bonding and van der Waals contacts with
distinct nucleobases in the cognate RNA molecules. Inspection of the available X-ray structure
(83) indicates that all IN residues implicated in RNA binding by the present study are positioned
either in the highly flexible C-terminal tail (aa 261-275) or the 252-257 loop (Fig. 5H). The pliable
nature of these CTD regions could be essential for allowing IN to optimally bind to cognate gRNA.
These observations extended to another class II mutant, R262A/R263A, whereby the D256R and
to a lesser extent the D256K substitutions restored RNA binding. In contrast, the D2N substitutions
did not enhance RNA-binding or infectivity in this setting, demonstrating a degree of context
dependency. It is possible that the proximity of the D270N to R269A/K273A residues may explain
why it was more effective in restoring RNA binding for this class II mutant but not for IN
R262A/R263A. The role of Arg and Lys residues in RNA-binding proteins has been noted (81).
Interestingly, Arg residues are overall more heavily involved in interactions with all bases,
contributing with 16%–20% of all contacts while Lys residues only provide 3%–9%, which may
explain why the D256R substitution restored RNA binding to a greater extent (40, 51, 85).
Altogether, our findings suggest that IN-gRNA binding is mediated in part by electrostatic
interactions between the basic residues in IN CTD and the negatively charged RNA backbone.
Though the electrostatic component of IN-RNA interactions imply a level of non-specificity, IN
bound to distinct locations on the gRNA and displays high binding affinity to structured elements,
such as the HIV-1 TAR element . Thus, it is likely that IN-gRNA interactions are mediated by
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both the non-specific interactions of the basic residues with the RNA phosphate backbone and
specific interactions with the cognate RNA. For example, recognition of the TAR loop by Tat and
the super elongation complex is based on a complex set of interactions that results primarily in the
readout of the structure as opposed to the sequence by SEC, and additional interaction of the Tat
arginine rich motif (ARM) with the TAR bulge and the major groove through electrostatic
interactions with the RNA phosphates, H-bonding with specific bases, as well as multiple van der
Waals contacts of Cyclin T with the flipped-out G32 TAR base to strengthen the TAR complex .
Structural studies of IN in complex with cognate RNA molecules are needed to tease apart the
specificity determinants for IN-RNA interactions.
RNA binding proteins commonly encode modular RNA-binding domains (i.e. RRMs and KH
domains), which form specific contacts with short degenerate sequences (13, 83, 86-88).
Utilization of multiple RRMs/KH domains is thought to create a much larger binding interface,
which allows recognition of longer sequences on and enhanced affinity and specificity for target
RNAs . IN tetramerization is required for RNA binding in vitro (43, 54, 89-92) and may serve a
similar purpose through generation of a larger RNA-binding surface possibly for recognition of
shape, RNA-backbone and base-specific interactions as discussed above.
IN-gRNA binding is essential for HIV-1 virion morphological maturation and infectivity, thus an
excellent target for novel antiretroviral compounds. Clinically used HIV-1 IN inhibitors target the
catalytic activity of IN by blocking the strand transfer step of integration . Despite high barriers to
resistance with the second-generation INSTIs, treatment continues to select for drug resistant HIV1 variants (94, 95). ALLINI-mediated inhibition of the non-catalytic function of IN can
complement existing INSTI-based therapies and increase the barrier to drug resistance
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substantially. Although some ALLINIs displayed toxicity in animals, a highly potent and safe
pyrrolopyridine-based ALLINI, STP0404, has advanced to a human trial (99, 100).
ALLINIs potently disrupt virion maturation indirectly through inducing aberrant IN
multimerization resulting in inhibition of IN-gRNA binding . Recent findings have shown that the
ALLINI, GSK-1264, is buried between the CTD of one IN dimer and the CCD of another dimer
resulting in the formation of open, inactive IN polymers (101). Mutation of Y226, W235, K264
and K266 residues within the CTD prevents ALLINI-induced aberrant multimerization of IN (67).
However, the role of these residues in ALLINI-mediated inhibition cannot be easily assessed in
relevant infection settings given that their mutation alters the catalytic activity as well as RNA
binding properties of IN (69). Our findings fill this gap and provide key genetic evidence that
ALLINI mechanism of action indeed involves the CTD. In particular, introducing the same D256R
change in the background of different class II substitutions similarly restored their infectivity and
thus enabled us to compare effects of R262/R263 vs R269A/K273A IN substitutions on ALLINI
activities. While HIV-1IN(R262A/R263A/D256R) and WT viruses were similarly susceptible to ALLINIs
(Fig. 7A,B), HIV-1IN(R269A/K273A/D256R) was substantially more sensitive to these inhibitors (Fig.
7D,E). The X-ray structure of GSK-1264 induced IN polymers (12, 73, 77, 102, 103) reveals that
R262, R263, K273A as well as D256 are distanced from the inhibitor binding pocket, whereas the
side chain of R269 points toward the inhibitor bound at the CTD-CCD dimer interface (Fig. 7G).
The guanidine group of R269 engages with Q168 of the CCD from another IN subunit and is
positioned within 3 Å of GSK-1264. Yet, there is no interaction between R269 and the inhibitor
as the positively charged guanidine group faces a hydrophobic part of the benzodihydropyran
moiety of GSK-1264 (Fig. 7G). Conversely, the R269A substitution could provide more favorable
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hydrophobic environment for the CTD-ALLINI-CCD interactions that may explain its increased
sensitivity to ALLINIs.
Overall, our studies reveal that electrostatic interactions play an important role in mediating INgRNA interactions and demonstrate that CTD is a key determinant of ALLINI sensitivity.
Structural characterization of IN-gRNA complexes will be crucial to determine the precise
mechanism of IN-gRNA interactions. Such studies will also help better understand the ALLINI
mechanism of action and aid in the development of therapeutics that directly target IN-gRNA
interactions.
2.6 Materials and methods
Plasmids
IN mutations were introduced into the HIV-1NL4-3 full-length proviral plasmid (pNL4-3) by overlap
extension PCR. Forward and reverse primers containing IN mutations were used in PCR reactions
with anti-sense (with EcoRI restriction endonuclease site) and sense (with AgeI restriction site)
outer primers. The resulting fragments containing the desired mutations were mixed at a 1:1 ratio
and overlapped subsequently using the sense and antisense primer pairs. The overlap fragments
were digested with Age-I and EcoR-I before cloning into pNL4-3 plasmids. The pLR2P-vprIN
plasmid expressing a Vpr-IN fusion protein has been previously described . IN mutations were
introduced in the pLR2P-VprIN plasmid using the QuikChange Site-Directed Mutagenesis kit
(Agilent Technologies). The presence of the desired mutations and the absence of unwanted
secondary changes was assessed by Sanger sequencing.
Cell lines
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All cell lines were obtained from the American Type Culture Collection and NIH AIDS Reagents
where STR profiling was performed. MT-4 cells were further STR profiled at Washington
University School of Medicine Genome Engineering and iPSC center. The cell lines are
consistently inspected for mycoplasma contamination using MycoAlert mycoplasma detection kit
(Lonza) and checked for being free of any other contaminations. HEK293T cells (ATCC CRL11268) and Hela-derived TZM-bl cells (NIH AIDS Reagent Program) were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum. MT-4 cells were cultured
in in RPMI 1640 medium supplemented with 10% fetal bovine serum.
Analysis of compensatory mutations
Compensatory mutations of the R269A/K273A class-II IN mutation were isolated by serial
passaging. In this experiment, MT4 T-cells that express GFP under the control of HIV-1 LTR
(MT4-LTR-GFP), were infected with HIV-1pNL4-3 carrying the R269A/K273A class II IN
mutation. One million cells were infected at an MOI of 2 by WT cells, input of mutant virus was
normalized relative to particle numbers using a reverse transcriptase (RT) activity assay .
Infections were monitored by FACS. At the end of each passage, virions were collected and
wielded to infect cells in the next passage while normalizing virus input before each infection.
Aliquots of infected and viral particles in the cell culture supernatants were collected over the
duration of each passage. Virions collected over the three passages were concentrated and gRNA
was isolated from virions using Trizol per manufacturer’s instructions. Extracted RNA was
prepared for deep sequencing usingthe Illumina® TruSeq® Stranded Total RNA library prep
workflow kit omitting the rRNA depletion step. Resulting libraries were sequenced by an Illumina
HiSeq 2000 platform.
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Immunoblotting
Viral and cell lysates were resuspended in sodium dodecyl sulfate (SDS) sample buffer, separated
by electrophoresis on Bolt 4-12% Bis-Tris Plus gels (Life Technologies) and transferred to
nitrocellulose membranes. The membranes were then probed overnight at 4°C with a mouse
monoclonal anti-HIV p24 antibody (183-H12-5C, NIH AIDS reagents) or a mouse monoclonal
anti-HIV integrase antibody in Odyssey Blocking Buffer (LI-COR). Membranes were probed
with fluorophore-conjugated secondary antibodies (LI-COR) and scanned using an LI-COR
Odyssey system. IN and CA levels in virions were quantified using Image Studio software (LICOR).
Vpr-IN trans-complementation experiments
Viruses bearing the class I IN mutation D116N were trans-complemented with class II mutant
proteins as previously described ; two-hundred thousand HEK293T cells were co-transfected with
a derivative of pNL4-3-derived plasmid bearing the IN D116N mutation, VSV-G, and derivatives
of the pLR2P-VprIN plasmids bearing class II IN mutations (or the compensatory mutations
thereof) at a ratio of 6:1:3. Cell-free virions were collected from cell culture two days posttransfection. MT-4 cells were infected by the virions and the integration proficiency of transcomplemented class II IN mutants was measured by the yield of progeny virions in cell culture
supernatants over a 6-day period as described before (4). Briefly, MT-4 cells were incubated with
virus inoculum in 96 V-bottom well plates for 4hr at 37°C before washing away the inoculum and
replacing it with fresh media. Right after the addition of fresh media and over the ensuing 6 days,
the number of virions in culture supernatant was quantified by measuring RT activity using a QPCR-based assay (15).
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CLIP experiments
CLIP experiments were conducted as previously described (10). In short, cells in 15 cm cell culture
plates were transfected with 30 μg full-length proviral plasmid (pNL4-3) DNA containing the WT
sequence or indicated IN mutations. 4-thiouridine (4SU) was added to the cell culture media for
16hr before virus harvest. Cell culture supernatants were filtered through 0.22 μm filters and
pelleted by ultracentrifugation through a 20% sucrose cushion using a Beckman SW32-Ti rotor at
28,000rpm for 1.5hr at 4°C. The virus pellets were resuspended in phosphate-buffered saline (PBS)
and UV-crosslinked. Following lysis in 1X RIPA buffer, IN-RNA complexes were
immunoprecipitated using a mouse monoclonal anti-IN antibody (106) . Bound RNA was endlabeled with γ-32P-ATP and T4 polynucleotide kinase. The isolated protein-RNA complexes were
separated by SDS-PAGE, transferred to nitrocellulose membranes, and exposed to
autoradiography films to visualize IN-RNA complexes. Lysates and immunoprecipitates were also
analyzed by immunoblotting using antibodies against IN.
IN multimerization in virions
In 10 cm dishes, HEK293T cells were transfected with 10 μg pNL4-3 plasmid DNA containing
the WT sequence or indicated pol mutations within IN coding sequence. Two days posttransfection, cell-free virions in cell culture supernatants were pelleted through a 20% sucrose
gradient using a Beckman SW41-Ti rotor at 28,000 rpm for 1.5hr at 4°C. Pelleted virions were
resuspended in 1xPBS and treated with a membrane-permeable crosslinker, EGS (ThermoFisher
Scientific), at a concentration of 1mM for 30 min at room temperature. Crosslinking was stopped
by the addition of SDS sample buffer. The cross-linked samples were then separated on 3-8% Trisacetate gels and analyzed by immunoblotting using a mouse monoclonal anti-IN antibody (107).
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Virus production and transmission electron microscopy
HEK293T cells in a 15 cm plate were transfected with 30 μg full-length proviral plasmid (pNL43) DNA containing the WT sequence or indicated pol mutations within IN coding sequence. Two
days post transfection, cell culture supernatants were filtered through 0.22 μm filters, and pelleted
by ultracentrifugation using a Beckman SW32-Ti rotor at 28,000 rpm for 1.5 hr at 4°C. Fixative
(2% paraformaldehyde/2.5% glutaraldehyde (Polysciences Inc., Warrington, PA) in 100 mM
sodium cacodylate buffer, pH 7.2) was gently added to resulting pellets, and samples were
incubated overnight at 4°C. Samples were washed in sodium cacodylate buffer and postfixed in
1% osmium tetroxide (Polysciences Inc.) for 1 hr. Samples were then rinsed extensively in dH20
prior to en bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for 1
hr. After several rinses in dH20, samples were dehydrated in a graded series of ethanol and
embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut with a Leica Ultracut
UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained with uranyl acetate and
lead citrate, and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc.,
Peabody, MA) equipped with an AMT 8 megapixel digital camera and AMT Image Capture
Engine V602 software (Advanced Microscopy Techniques, Woburn, MA).
Size exclusion chromatography (SEC)
All of the indicated mutations were introduced into a plasmid backbone expressing His6 tagged
pNL4-3-derived IN by QuikChange site directed mutagenesis kit (Agilent) (1, 108). His6 tagged
recombinant pNL4-3 WT and mutant Ins were expressed in BL21 (DE3) E. coli cells followed by
nickel and heparin column purification as described previously . Recombinant WT and mutant Ins
were analyzed on Superdex 200 10/300 GL column (GE Healthcare) with running buffer
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containing 20 mM HEPES (pH 7.5), 1 M NaCl, 10% glycerol and 5 mM BME at 0.3 mL/min flow
rate. The proteins were diluted to 10 µM with the running buffer and incubated for 1 h at 4°C
followed by centrifugation at 10,000g for 10 min. Multimeric form determination was based on
the standards including bovine thyroglobulin (670,000 Da), bovine gamma-globulin (158,000 Da),
chicken ovalbumin (44,000 Da), horse myoglobin (17,000 Da) and vitamin B12 (1,350 Da).
Retention volumes for different oligomeric forms of IN were as follows: tetramer ~12.5 mL, dimer
~14 mL, monomer ~15-16 mL.
Analysis of IN-RNA binding in vitro
To monitor IN-RNA interactions we utilized AlphaScreen-based assay (1), which allows to
monitor the ability of IN to bind and bridge between two TAR RNAs. Briefly, equal concentrations
(1 nM) of two synthetic TAR RNA oligonucleotides labeled either with biotin or DIG were mixed
and then streptavidin donor and anti-DIG acceptor beads at 0.02 mg/mL concentration were
supplied in a buffer containing 100 mM NaCl, 1 mM MgCl2, 1 mM DTT, 1 mg/mL BSA, and 25
mM Tris (pH 7.4). After 2 hr incubation at 4°C, 320 nM IN was added to the reaction mixture and
incubated further for 1.5 hr at 4°C. AlphaScreen signals were recorded with a PerkinElmer Life
Sciences Enspire multimode plate reader.
Structural modeling of IN
Electrostatic potential maps of WT and mutant IN CTDs were created by Adaptive PoissonBoltzmann Solver (APBS) program (2) with macromolecular electrostatic calculations performed
in PyMOL. The published crystal structure (3) (PDB ID: 5HOT) was used as a template. The
calculation results are displayed as an electrostatic potential molecular surface. The low, mid, and
high range values are -5, 0, and 5, respectively.
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Analysis of IN mutations from latently infected cells
Sequences identified from latently infected CD4+ T-cells (4) were downloaded from NCBI
GenBank based on their accession numbers (KF526120-KF526339). Sequences were imported
into the GLUE software framework (5) and aligned. Multiple sequence alignments (MSAs)
containing subtype B and subtype C sequences were constructed using MUSCLE, manually
inspected in AliView (6) and imported into a GLUE project database. Within GLUE, MSAs were
constrained to the pNL4-3 reference to establish a standardized coordinate space for the gene being
analyzed. Amino acid frequencies at each alignment position were summarized using GLUE’s
amino-acid frequency calculation algorithm, which accounts for contingencies such as missing
data and incomplete codons.
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3.1 Introduction
For decades, the HIV-1 integrase (IN) was solely known for catalyzing the 3’ end processing and
strand transfer reactions which lead to integration of the newly reverse transcribed viral DNA
(vDNA) into the host chromosome (5, 7-9). Recent findings from our lab have showed that
integrase binds to the viral genomic RNA (gRNA) in mature virion particles (10-12).
Crosslinking immunoprecipitation coupled with next generation sequencing (CLIPseq) show that
IN binds to multiple distinct regions of the gRNA including TAR, a hairpin within the 5’ and 3’
UTRs of the HIV-1gRNA (12). Furthermore, in vitro binding assays showed that IN had
particularly high binding affinity for TAR (12). This RNA-binding property of IN is essential
for maturation of virion particles; class II IN mutations and allosteric integrase inhibitors
(ALLINIs) cause a virion deformation referred to as eccentric morphology by inhibiting INgRNA binding (10, 12-22). The eccentric morphology of HIV-1 virions is characterized by the
mislocalization of the viral ribonucleoprotein complex (vRNP) outside of the capsid lattice (10,
12-22). The gRNA and IN of eccentric virions gets degraded in the earliest stages of the HIV
replication cycle (11, 23).
Our previous studies have shown that IN binds to gRNA as a tetramer and the binding is
mediated by electrostatic affinity between basic residues of the IN C-terminal domain (CTD) and
the negatively charged phosphodiester RNA backbone (10). This observation led to the question
of whether IN only specifically binds to the viral gRNA. For instance, although the IN has high
affinity for the TAR region on 5’ UTR gRNA, it also binds to discrete regions all around the
length of gRNA. In this chapter, we used CLIPseq (described in 3.2) and in vitro binding assays
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to show that IN binds to gRNA regions rich in adenosine and guanosine nucleotides (A-G).
Further, CLIP experiments showed that IN could bind to non-viral RNA packaged by virions.
Altogether, these observations suggested that the binding of IN to RNA might be semi-specific
in nature.
The RNA-binding property of IN is essential for the formation of replication competent
virions, which makes it a great target for the future antiretroviral agents. The presence of
ALLINIs in virion producer cells inhibits IN-gRNA binding by causing aberrant IN
multimerization (10-12, 23). However, there has been no evidence that IN binds to gRNA in
producer cells before virion release as gRNA is packaged and condensed by the nucleocapsid
(NC) protein in virions (12). In this chapter, we describe our investigations and findings on
whether IN binds to RNA before or after virions release; such information could be very useful
in designing less toxic and more potent ALLINIs. The development of IN-gRNA binding
inhibitors will depend on a full understanding of the IN-gRNA complex structures. Nonetheless,
integrase protein has been virtually impossible to crystallize by standard structural biology
techniques due to its low solubility (24-28). This chapter details our new approaches for
isolating and resolving the structures of IN-gRNA complexes.

3.2 Identifying the RNA targets of RNA binding proteins with CLIP
Viruses containing RNA genomes as their genetic material (i.e. RNA viruses and retroviruses)
cause a number of diseases ranging from the common cold to AIDS, and are major contributors
to the global infectious disease burden. To replicate and propagate their RNA genomes, these
viruses must efficiently utilize host cell machinery to facilitate a number of processes including
viral RNA transcription, splicing, transport between subcellular compartments and translation.
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Viral RNAs also must retain unique sequence and structural features in order for recognition by
viral RNA binding proteins (RBPs) that mediate RNA polymerization and export, selective
genome packaging, RNA localization in virions, and RNA stability during early stages of
infection. While beneficial for virus replication, the distinct features of viral RNAs can also be
recognized as foreign by several host defense proteins that mount antiviral defenses through the
production of cytokines upon binding to viral RNAs. In sum, a myriad of protein-RNA
interactions play crucial roles in the life cycle of viruses, and as such identifying these
interactions is crucial to understanding their pathogenesis.
Development of the CLIP approach has revolutionized the study of protein-RNA interactions
(29-32). Traditionally, RBP-RNA interactions have been studied by methods that required the
a priori knowledge of the binding site, such as in vitro binding assays or purification of proteinRNA complexes from cell lysates with downstream analysis of bound RNA by Q-RT-PCR.
Coupling of protein-RNA complex isolation with microarray analysis, and more recently, high
throughput sequencing provided a more global picture of the bound RNAs, but suffered from
high background and low specificity due to purification of non-specific RNAs or multiple RBPs
in complex with their bound RNAs (33, 34). While in vitro approaches such as SELEX (35, 36),
RNA-compete (37), RNA-bind-n-Seq (38), and RNA-Map (39) can provide detailed nucleotide
resolution information of the target site and the biochemical properties of these interactions, they
cannot determine which sequence the RBP of interest will bind to at physiologically relevant
concentrations. What makes CLIP a powerful approach is that it addresses all of the
shortcomings of these previous approaches by yielding nucleotide resolution information of the
RNA molecules bound by the RBP of interest in physiological settings, ranging from virus
particles to animal tissues, at a global scale.
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The key steps of the existing CLIP methodologies are (Figure 1): (1) Protein-RNA complexes
are covalently crosslinked in live cells/tissues/virions typically by UV crosslinking; (2)
Cells/tissues/virions are lysed and treated with limited amounts of RNases leaving small
fragments of RNA molecules (~20–50 nucleotides) protected by the protein of interest; (3)
Protein-RNA complexes are immunoprecipitated, and non-specific RNAs and proteins are
removed by stringent washes. Because the protein-RNA complexes are covalently crosslinked,
these stringent conditions, in principle, do not affect purification of target protein-RNA adducts.

Figure 1. Schematic diagram of steps involved in PAR-CLIP experiments.
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(4) The purified protein-RNA complexes are radioactively labeled and separated by SDS-PAGE.
(5) Bound RNA is isolated by Proteinase K treatment. (5) Eluted RNA is ligated to adapters,
reverse transcribed, and the resulting cDNA is PCR amplified and subjected to sequencing. (6)
Sequencing reads are processed and mapped to reference genomes. Depending on the method
used, the resulting library contains nucleotide substitutions or deletions (40) at the site of
crosslinking, which allows mapping of the site of protein-RNA interactions at nucleotide
resolution.

Various versions of CLIP have been developed and the details of these alternative
approaches have been reviewed elsewhere (33, 41). The approach we commonly use depends on
efficient UV crosslinking mediated by ribonucleoside analogs, including 4-thiouridine (4SU) and
6-thioguanosine (6SG), as in the original PAR-CLIP protocol (29). In PAR-CLIP experiments,
cells are grown in the presence of ribonucleoside analogs for up to 16 hours and UV-crosslinked
at a longer wavelength (365 nm). With the majority of the viral and cellular RNA-binding
proteins we studied in the past few years, this method significantly enhanced the amount of
protein-RNA adducts obtained (12, 42-44). In addition, PAR-CLIP allows accurate nucleotide
resolution mapping of target RNA sites due to mutations introduced by the reverse transcriptase
enzyme (T-to-C for 4SU and G-to-A for 6SG) precisely at the site of crosslinking during cDNA
synthesis. On the other hand, use of ribonucleoside analogs may inadvertently enrich RNA
elements with distinct nucleotide composition or alter RNA structure (45), which may
subsequently affect protein binding. Thus, we routinely validate our findings with the use of both
ribonucleoside analogs and HITS CLIP, which utilizes conventional UV-crosslinking.
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For library generation, we follow a combination of PAR-CLIP and HITS-CLIP protocols (3032). As reviewed elsewhere (33, 34, 41), this is the stage where most variant CLIP protocols
differ. While the HITS-CLIP and many other protocols call for ligation of adapters while the
protein-RNA complexes are on beads, the solution-phase PAR-CLIP library generation protocol
was significantly more efficient in our experience with 3’ and 5’ adapter ligations routinely
functioning at >90% efficiency. Another common alternative is the utilization of a two-part
cleavable adapter introduced into cDNA during reverse transcription in the iCLIP approach (46).
This is followed by circularization and restriction enzyme digestion, which allows the recovery
of a larger fraction of truncated cDNAs a result of reverse transcriptase stalling at crosslinking
sites. Due to this enrichment, iCLIP can yield higher complexity libraries and has been proposed
to perform better than previous approaches in identification of the precise site of crosslinking
(46-48).
All CLIP approaches are technically challenging with numerous labor-intensive steps. In
addition, the loss of the starting material at several inefficient steps is a major drawback. This
problem is further exacerbated if the initial protein-RNA complexes are not abundant due to low
levels of expression, low crosslinking or immunoprecipitation efficiencies. These problems can
often lead to a final library with insufficient complexity and over-enrichment of environmental
contaminating sequences.

3.3 Integrase preferably binds to purine-rich sequences on viral RNA
Although CLIPseq and in vitro binding assays have shown that IN has high affinity for TAR, a
hairpin structure within the 5’ UTR of gRNA (12), CLIPseq also shows that IN binds to gRNA
sequences without distinguishable secondary structure. Altogether, the nature of IN-gRNA
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binding is poorly understood, and it is not certain whether the binding is specific or IN binds to
distinct characteristic sequences of viral gRNA. The version of CLIP (PAR-CLIP) that has
previously been used to study IN-gRNA binding relies on the incorporation of photoreactive
analogs such as 4-thiouridine (4-SU) into nascent gRNAs in producer cells (12, 49); this
enhances the efficiency of crosslinking, the amount IN-gRNA adducts that are
immunoprecipitated, and helps identify IN-gRNA binding sites at nearly nucleotide resolution.
Although the incorporation of 4-SU is very helpful, it can bias binding site identification towards
U-rich elements. We used a guanosine analog, 6-thioguanosine (6-SG), in CLIP experiments to
get a distinct picture of gRNA elements that are bound IN. The 6-SG based CLIPseq identified
more distinctive binding sites with high frequency (Figure 2A). A deeper analysis of the motifs
within the binding sites showed that IN binds to A/G rich (Figure 2B) sequences most of which
contained the 5’-GGAAAGGA-3’ sequence.

Figure 2. Purine-rich sequences are preferentially bound by IN. A. CLIP was performed on
virions generated in the presence of 4-SU and 6-SG. Footprints of IN on the 9kb viral genome is
shown. B. Meme plot of the most prevalent nucleotides in integrase bound regions.
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This observation was validated through in-vitro biochemical binding assays in collaboration with
Dr. Mamuka Kvaratskhelia’s lab at the University of Colorado. IN showed high propensity to
binding the 5’-GGAAAGGA-3’ consensus sequence, but not its reverse complement or the
double stranded form (Figure. 3A). Furthermore, the addition of purine nucleotides to the 5’ and
3’ of the sequence increased the binding affinity to IN (Figure 3B).

Figure 3. Purine-rich sequences are preferentially bound by IN. A. In vitro assessment of IN binding
affinity to the 5’-GGAAAGGA-3’ RNA sequences (black), its reverse compliment (red), or its double
stranded version (blue). B. Similar to A but with addition of several AG nucleotides on both ends of the
5’-GGAAAGGA-3’ sequence.

The observed high binding frequency and affinity of IN to purine-rich sequences might be a
result of the fact that the HIV-1 genome has a particularly high A-nucleotide content (50, 51). In
the absence of HIV-1 gRNA, virions can package cellular RNAs (52). To test whether IN can
bind to non-viral packaged RNA, we generated virus like particles (VLPs) devoid of the viral
genome but package cellular RNA. These VLPs were made using plasmids bearing a CMV
promoter driving the expression of a synthetic codon-optimized Gag-Pol (SYNGP) gene. CLIP
autoradiographs show that IN in VLPs could bind to RNA (Figure 4A). Moreover, the ALLINI
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BI-D and class II mutation R269A/K273A blocked RNA binding (Figure 4B). Although this
observation suggests that IN can bind to cellular RNAs, it remains unclear whether IN binds to
purine rich sequences on these RNAs as of now. CLIP to identify IN-bound sequences from the
VLPs will be instrumental to distinguish whether the observed RNA-binding specificity of IN is
a result of AG-rich genome content or specific interaction of IN with purine rich sequence
elements.

Figure 4. HIV-1 IN can bind to cellular RNAs in the absence of the genome. A, synGP and NLGPderived VLPs were subjected to CLIP analysis alongside with full-length NL4-3. B, synGP-derived
VLPs bearing the R269A/K273A substitution and grown in the presence of 10 uM BI-D were
subjected to CLIP. Autorads displaying IN-RNA complexes are shown on top. W.blots of IN and CA
are shown on the bottom.

3.4 Conservation of integrase-RNA binding in retroviruses
IN-gRNA binding is essential for maturation of HIV-1 virions (10-12, 23). Following the release
of immature virions from cells, the protease domain of Gag-Pol cleaves Gag and Gag-Pol into
their constituent domains which triggers the reorganization of these proteins into a mature HIV-1
virion. In mature HIV-1virions, the capsid lattice surrounds the viral ribonucleoprotein complex
(53, 54). While proteolytic cleavage of Gag and Gag-Pol polyproteins during particle maturation
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is common to all retroviruses, virion morphologies vary widely. Looking at different retroviral
species, the capsids of mature virions adopt a multitude of shapes and sizes (Figure 5)(55). While
HIV-1 and lentivirus capsid lattices are mostly cone-shaped (56-59), retroviruses such as RSV
and MLV display polyhedral or nearly spherical capsids (58-62). It has been shown that HTLV-1
has a poorly defined polyhedral capsid, with angular polygon-like regions and at least one curved
region in each capsid (63).

Figure 5. Morphology of mature retrovirus virions. RSV: Rous sarcoma virus (1, 2), MMTV:
mouse mammary tumor virus (1-3), MoMLV: Moloney murine leukemia virus , HTLV-1: human Tcell leukemia virus type 1 (4), HIV-1: human immunodeficiency virus type 1(5), FV: Foamy virus (6,
7). The FV Gag protein is not processed into the classical orthoretroviral MA, CA, and NC subunits
during particle morphogenesis. The black arrowheads show regular Gag assemblies in the wild type
virus .
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It is currently unknown whether IN-gRNA binding is essential for the encapsidation of the vRNP
of all retroviruses. Using CLIP, we have investigated whether IN binds to the genomic RNA in
other retroviruses: lentiviruses (HIV-1, MVV, and EIAV), beta-retrovirus (MMTV), deltaretrovirus (HTLV-1), and gamma-retrovirus (MLV). IN-RNA adducts on our CLIP
autoradiographs show that IN binds to the genomic RNA of such viruses (Figure 6).
Furthermore, some of the mutations that were predicted as class II mutations based on alignment
with HIV-1 IN sequence also inhibited IN-gRNA (Figure 6). The introduction of such mutations
in some viruses, however, resulted in loss of IN in virions and the mutations were thus not
interpretable (Figure 6). These initial findings show that IN-gRNA binding is conserved across
retroviruses, and they suggest that so might the role of IN in virion morphogenesis. Our future
experiments will focus on more detailed characterization of class II phenotype with other
retroviruses using a combination of thin section electron microscopy and CLIP to investigate
how inhibition of IN-gRNA binding affects retroviral morphology.

Figure 6. Autoradiographs (top) showing IN-RNA adducts and Western blots of IN (bottom) in
MLV, EIAV, MVV, and MMTV
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3.5 Discussion
This chapter provides tools and data that can serve as the basis for further studies into how INRNA binding regulates the morphogenesis of HIV-1 and other retroviruses. CLIP not only
provides a powerful tool to identify whether a protein of interest binds to RNA in physiologically
relevant settings, but it also permits to identify protein-bound sequences at nearly nucleotide
resolution. CLIPseq has revealed that HIV-1 IN preferentially binds to AG-rich sequences on the
genomic RNA packaged inside virions. Furthermore, in vitro binding assays have shown that IN
has higher binding affinity for AG-rich sequences. Although IN binds to specific sequences of
the viral genomic RNA with high affinity, we observed that IN can also bind to packaged
cellular RNAs in the absence of the viral genome. This observation suggests that the binding of
IN-gRNA is semi specific. The nature of IN-gRNA will not be completely understood until the
structure of IN-gRNA complexes is available. Over the years, studying the full structure of IN
has been nearly impossible with traditional protein isolation methods due to the low solubility of
integrase. We are building immunoprecipitation-based tools to purify IN-RNA complexes from
virions, and initial findings show that full length IN is isolated with relatively high efficiency.
The structure of IN complexes purified in such ways can be resolved using cryo-EM through our
existing collaborations. Over and above that, we show that IN-RNA binding is conserved in
other retroviruses. Characterizing the structure and properties of IN-gRNA binding and the
molecular mechanism through they regulate virion morphology will be crucial in designing a
new class of integrase-targeting antiretroviral agents.
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4.1 Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions within
just a few months causing severe respiratory disease and mortality. Assays to monitor SARSCoV-2 growth in vitro depend on time-consuming and costly RNA extraction steps, hampering
progress in basic research and drug development efforts. Here we developed a simplified
quantitative real-time PCR (Q-RT-PCR) assay that bypasses viral RNA extraction steps and can
monitor SARS-CoV-2 growth from a small amount of cell culture supernatants. In addition, we
show that this approach is easily adaptable to numerous other RNA and DNA viruses. Using this
assay, we screened the activities of a number of compounds that were predicted to alter SARSCoV-2 entry and replication as well as HIV-1-specific drugs in a proof of concept study. We
found that E64D (inhibitor of endosomal proteases cathepsin B & L) and apilimod (endosomal
trafficking inhibitor) potently decreased the amount of SARS-CoV-2 RNA in cell culture
supernatants with minimal cytotoxicity.,Surprisingly, we found that the macropinocytosis
inhibitor EIPA similarly decreased SARS-CoV-2 RNA levels in supernatants suggesting that
entry may additionally be mediated by an alternative pathway. HIV-1-specific inhibitors
nevirapine (an NNRTI), amprenavir (a protease inhibitor), and ALLINI-2 (an allosteric integrase
inhibitor) modestly inhibited SARS-CoV-2 replication, albeit the IC50 values were much higher
than that required for HIV-1. Taken together, this simplified assay will expedite basic SARSCoV-2 research, be amenable to mid-throughput screening assays (i.e. drugs, CRISPR, siRNA,
etc.), and be applicable to a broad number of RNA and DNA viruses.

91

4.2 Importance
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the
COVID-19 pandemic is continuing to cause immense respiratory disease and social and
economic disruptions. Conventional assays that monitor SARS-CoV-2 growth in cell culture rely
on costly and time-consuming RNA extraction procedures, hampering progress in basic SARSCoV-2 research and development of effective therapeutics. Here we developed a simple
quantitative real-time-PCR assay to monitor SARS-CoV-2 growth in cell culture supernatants
that does not necessitate RNA extraction, and is as accurate and sensitive as existing methods. In
a proof-of-concept screen, we found that E64D, apilimod, EIPA and remdesivir can substantially
impede SARS-Cov-2 replication providing novel insight into viral entry and replication
mechanisms. In addition, we show that this approach is easily adaptable to numerous other RNA
and DNA viruses. This simplified assay will undoubtedly expedite basic SARS-CoV-2 and
virology research, and be amenable to drug screening platforms to identify therapeutics against
SARS-CoV-2.
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4.3 Observation
Severe acute respiratory syndrome coronavirus, SARS-CoV-2 is continuing to cause substantial
morbidity and mortality around the globe (1, 2). Lack of a simple assay to monitor virus growth
is slowing progress basic SARS-CoV-2 research as well as drug discovery. Current methods to
quantify SARS-CoV-2 growth in cell culture supernatants rely on time-consuming and costly
RNA extraction protocols followed by quantitative real-time PCR (Q-RT-PCR) (3). In this study,
we developed a simplified Q-RT-PCR assay that bypasses the RNA extraction steps, can detect
viral RNA from as little as 5 μL of cell culture supernatants and works equally well with
TaqMan and SYBR-Green-based detection methods.
A widely used assay to measure virus growth in the retrovirology field relies on determining the
activity of virion-associated reverse transcriptase enzyme collected from a small amount of
infected cell culture supernatants (4). We reasoned that we could adapt this approach to monitor
SARS-CoV-2 growth. First, we tested whether the more stringent lysis conditions used to
inactivate SARS-CoV-2 would interfere with the subsequent Q-RT-PCR step. To do so, 5 μL of
serially diluted RNA standards prepared by in vitro transcription from a plasmid containing the
entire SARS-CoV-2 nucleoprotein (N) gene were mixed with 5 μL of 2x RNA lysis buffer (2%
Triton X-100, 50 mM KCl, 100 mM TrisHCl pH7.4, 40% glycerol, 0.4 U/μL of SuperaseIN
(Life Technologies)), followed by addition of 90 μL of 1X core buffer (5 mM (NH4)2SO4, 20
mM KCl and 20 mM Tris–HCl pH 8.3). 8.5 μL of the diluted samples were added to 11.5 μL of
a reaction mix consisting of 10 μL of a 2x TaqMan RT-PCR mix, 0.5 μL of a 40x Taqman RT
enzyme mix (containing ArrayScript™ UP Reverse Transcriptase, RNase Inhibitor), and 1 μL of
a mixture containing 10 pmoles of forward and reverse primers as well as 2 pmoles of Taqman
Probe Table S1) resulting in a final reaction volume of 20 μL. The reactions were run on the
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ViiA™ 7 Real-Time PCR system (Applied Biosystems) using the following cycling parameters:
48 oC for 15 min, 95oC for 10 min, 50 cycles of 95oC for 15 sec and 60oC for 1 min of signal
acquisition. We found that the modified sample preparations did not impact the sensitivity,
efficiency or the dynamic range of the Q-RT-PCR assay as evident in the virtually identical cycle
threshold (Ct) values obtained for a given RNA concentration and the similar slopes of linear
regression curves (Fig. 1A).
To determine whether this approach would work equally well for virus preparations, 100 μL of
virus stock (1.4x105 pfu) was lysed via the addition of an equal volume of buffer containing 40
mM TrisHCl, 300 mM NaCl, 10 mM MgCl2, 2% Triton X-100, 2 mM DTT, 0.4 U/µL
SuperaseIN RNase Inhibitor, 0.2% NP-40. RNA was then extracted using the Zymo RNA clean
and concentratorTM-5 kit and was serially diluted afterwards. In parallel, 5 μL of virus stock and
its serial dilutions prepared in cell culture media were lysed in 2X RNA lysis buffer and
processed as above. Samples were analyzed by Q-RT-PCR alongside with RNA standards. A
standard curve was constructed by plotting the cycle threshold (Ct) value against the
corresponding log2(copy number) of the RNA standards, which was subsequently used to
determine copy numbers in samples. We then calculated the number of copies per milliliter of
the original virus stock, assuming 100% recovery for samples subjected to RNA extraction. We
found that the modified assay performed equivalently well, if not better, with a similarly broad
dynamic range (Fig. 1B).
We next used this assay to monitor virus growth on infected Vero cells. Cell culture supernatants
containing virus collected at various times post infection were either used to extract viral RNA or
subjected to Q-RT-PCR directly (non-extracted) as above. The modified assay with nonextracted samples yielded virtually identical number of copies/mL of SARS-CoV-2 RNA in cell
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culture supernatants even at low concentrations of viral RNAs (Fig. 1C). Collectively, these
results suggest that RNA extraction from cell culture supernatants can be bypassed without any
compromise on the sensitivity or the dynamic range of Q-RT-PCR detection.
Next, we wanted to test whether this assay could work equally well with SYBR-Green-based
detection methods. In addition to the N primer pair used in the above TaqMan-based assays, we
utilized the N2 primer set designed by CDC and targeting the N region of the SARS-CoV-2
genome (Table S1). Serially diluted RNA standards were processed in RNA lysis and core
buffers, and 7.5 uL of each dilution was used in a 20 uL SYBR-Green Q-RT-PCR reaction
containing 10μL of a 2X POWERUP SYBR Green mix (Life Technologies ref: A25742),
1.25units/ μL of MultiScribe Reverse Transcriptase (Applied Biosystems), 1X random primers
and 25 pmoles of forward and reverse primers. Both primer pairs yielded reasonably broad
dynamic ranges, but were modestly less sensitive than TaqMan-based assays with a detection
limit of ~3500 RNA copies/mL (Fig. 1D).
We next tested whether this simplified Q-RT-PCR assay can be adapted to other RNA and DNA
viruses. Dilutions of stocks of influenza A virus (IAV/PR8), herpes simplex virus type-2 (HSV2), alphaviruses (Ross River virus (RRV), Chikungunya virus (CHIKV), Mayorovirus (MAYV))
and flaviviruses (Dengue virus (DENV-4), West Nile virus (WNV NY99) and Zikavirus (ZIKVDakar)) collected from cell culture supernatants were either subjected to RNA/DNA extraction
or the simplified lysis protocol as above followed by SYBR-Green or Taqman-based Q-RT-PCR
with the indicated primers (Table S1). For HSV-2, the reaction mixture did not include the
reverse transcription enzyme and the initial reverse transcription step was skipped. We found that
for IAV (Fig. 1E), HSV-2 (Fig. 1F) and RRV (Fig. 1G), the non-extracted samples worked
equally well, and for CHIKV non-extracted samples gave lower Ct values across various virus
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dilutions (Fig. 1H). For MAYV the dynamic range obtained from non-extracted samples was low
compared to extracted samples (Fig. 1I), likely due to the incompatibility between lysis and PCR
conditions. Although the Ct values were generally higher for non-extracted samples of ZIKV
(Fig. 1J), WNV (Fig. 1K) and DENV (Fig. 1L), the dynamic range was still broad with similar
PCR efficiencies between extracted and non-extracted samples. Taken together, these results
demonstrate that the simplified Q-RT-PCR developed here can in principle be easily adapted to a
large number of viruses provided that the lysis conditions are appropriate and working primer
sets are present.
One immediate application of this simplified assay is in mid-throughput drug screening
platforms (i.e. compound, CRISPR, siRNA screens) given the ease of quantitatively assessing
viral growth from small quantities of cell culture media containing virions. To demonstrate this,
we next conducted a proof-of-concept drug screen to validate the antiviral activities of various
compounds that have been reported to inhibit SARS-CoV-2 and HIV-1 replication as well as
non-specific entry inhibitors (Table S2). Vero E6 cells plated in 96-well plates were infected in
the presence of varying concentrations of the indicated compounds. Viral RNA in cell culture
supernatants was quantified by the SYBR-Green-based Q-RT-PCR assay as above at 6, 24 and
48 hpi. Compound cytotoxicity was assessed in parallel by the RealTime-Glo™ MT Cell
Viability Assay (Promega). While viral RNA was at background levels at 6 hpi (data not shown),
we found that, at 24hpi, remdesivir (inhibitor of RNA-dependent RNA polymerase, (5)), E64D
(inhibitor of the endosomal protease cathepsin B, K and L), and apilimod (PIKfyve inhibitor
resulting in endosomal trafficking defects, (6, 7)) substantially decreased SARS-CoV-2 viral
RNAs in supernatants (Fig. 2). IC50 values of these compounds (2.8 μg/mL (remdesivir), 3.3 μM
(E64D) and 12nM (apilimod)) were within the same range of published IC50 values of these
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compounds (6-8) (Fig. 2). Similar results were obtained at 48 hpi, albeit E64D and apilimod
appeared to be less potent at this time point either due to virus overgrowth or compound turnover
(data not shown). We found that EIPA, which inhibits Na+/H+ exchanger and macropinocytosis,
substantially decreased viral RNA in supernatants at sub-cytotoxic levels (Fig. 2D), suggesting
that macropinocytosis may contribute to viral entry and/or subsequent steps in virus replication.
HIV-1 specific inhibitors nevirapine, amprenavir and ALLINI-2 modestly inhibited SARS-CoV2 replication without apparent cytotoxicity at high concentrations, albeit the concentrations
required for this inhibition were much higher than those that inhibit HIV-1 (Fig. S1). Overall,
these findings demonstrate that this simplified assay can be adapted for screening platforms and
support previous reports which demonstrated that SARS-CoV-2 entry is dependent on processing
of the Spike protein by cellular proteases and requires endosomal fusion (7, 9, 10).
In conclusion, we have developed a simple Q-RT-PCR assay to monitor the growth of
SARS-CoV-2 as well as other viruses from cell culture supernatants, bypassing the time
consuming and costly RNA extraction procedures. This simplified assay will undoubtedly
expedite basic SARS-CoV-2 research, might be amenable to mid-throughput screens to identify
chemical inhibitors of SARS-CoV-2 and can be applicable to the study of numerous other RNA
and DNA viruses.
4.4 ACKNOWLEDGEMENTS
We thank members of the Whelan, Diamond and Amarasinghe labs for their generosity in
providing reagents and support. This study was supported by Washington University startup
funds to SBK, NIH grant U54AI150470 (the Center for HIV RNA Studies) to SBK,
1U01AI151810 - 01 to ACMB, NSF grant DGE-1745038 to HRV and Stephen I. Morse

97

fellowship to MPC. The Boon laboratory has scientific research agreements with AI therapeutics,
Greenlight Biosciences and Nano Targeting & Therapy Biopharma Inc.

98

Figure 1. Development of a simplified Q-RT-PCR assay for SARS-CoV-2 viral RNA detection in cell
culture supernatants. A. Serially diluted RNA standards were either directly subjected to Q-RT-PCR or
processed as in the modified protocol detailed in the text prior to Q-RT-PCR. Log2 (copies) are plotted
against the cycle threshold (Ct) values. Linear regression analysis was done to obtain the equations. Data
show the average of three independent biological replicates. Error bars show the SEM. B. Comparison of
the efficiency and detection ranges for quantifying SARS-CoV-2 RNA using purified RNA or lysed
supernatants from virus stocks. Data are derived from three independent replicates. Error bars show the
SEM. C. Vero E6 cells were infected at an MOI of 0.01 and cell culture supernatants were analyzed for
SARS-CoV-2 RNA following the conventional RNA extraction protocol vs. the modified protocol
developed herein at various times post infection. Cell-associated viral RNA was analyzed in parallel
following RNA extraction for reference. Data are from three independent biological replicates. Error bars
show the SEM. D. Illustration of the efficiency and detection ranges of Taqman-based and SYBR-Greenbased Q-RT-PCR quantifying known amounts of SARS-CoV-2 RNA. Data is from 2-3 independent
replicates. Error bars show the SEM. E-L. Indicated viruses were subjected to RNA or DNA extraction
(extracted) and diluted 10-fold, or used directly following dilution (non-extracted) in the SYBR-Green EI. or Taqman-based (J-L) Q-RT-PCR assay as above. Samples were normalized such that equivalent
amount of the original virus stock was added to PCR reactions for extracted and non-extracted samples.
Plots show the corresponding cycle threshold (Ct, y-axis) per virus dilution (x-axis). Data are from two
independent replicates with error bars showing the SEM.
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Fig 2. A compound screen to validate SARS-CoV-2-specific inhibitors and entry pathways. Vero E6
cells were infected with SARS-CoV-2 at an MOI of 0.01 and inhibitors were added concomitantly at
concentrations shown in the figures following virus adsorption. Supernatants from infected cells were lysed
and used in a SYBR-Green based Q-RT PCR to quantify the viral RNA in cell culture supernatants.
Compound cytotoxicity was monitored by RealTime-Glo™ MT Cell Viability Assay Kit (Promega) in
parallel plates. Data show the cumulative data from 2-5 independent biological replicates. Error bars show
the SEM.
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Fig S1. A screen to test the antiviral activities of various HIV-1-specific inhibitors. Vero E6 cells were
infected with SARS-CoV-2 at an MOI of 0.01 and inhibitors were added concomitantly at concentrations
shown in the figures following virus adsorption. Supernatants from infected cells were lysed and used in a
SYBR-Green based Q-RT PCR to quantify the viral RNA in cell culture supernatants. Compound
cytotoxicity was monitored by RealTime-Glo™ MT Cell Viability Assay Kit (Promega) in parallel plates.
Data show the cumulative data from 2-3 independent biological replicates. Error bars show the SEM.
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Table S1. Sequences of the primers and probes used in this study
Virus (Gene)
SARS-CoV-2 (N)
SARS-CoV-2 (N)
SARS-Cov-2 (N)
SARS-CoV-2 (N2)
SARS-CoV-2 (N2)
IAV A/PR8/34 (M)
IAV A/PR8/34 (M)
HSV-2 (ICP27)
HSV-2 (ICP27)
CHIKV (E1)
CHIKV (E1)
RRV (nsP3)
RRV (nsP3)
MAYV (nsp1-3)
MAYV (nsp1-3)
ZIKV-Dakar (pp)
ZIKV-Dakar (pp)
ZIKV-Dakar (pp)
WNV-NY99 (pp)
WNV-NY99 (pp)
WNV-NY99 (pp)

Primer/Probe Sequence (Forward/Reverse)
5’-ATGCTGCAATCGTGCTACAA-3’ (F)
5’-GACTGCCGCCTCTGCTC-3’ (R)
5’-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/
5’-TTACAAACATTGGCCGCAAA-3’ (F)
5’-GCGCGACATTCCGAAGAA-3’ (R)
5’-AAGACCAATCCTGTCACCTCTGA-3’ (F)
5’-CAAAGCGTCTACGCTGCAGTCC-3’ (R)
5’-TGT CGG AGA TCG ACT ACA CG-3’ (F)
5’-CGGTGCGTGTCCAGTATTTC-3’ (R)
5’-TCGACGCGCCCTCTTTAA-3’ (F)
5’-ATCGAATGCACCGCACAC T-3’ (R)
5’-GTGTTCTCCGGAGGTAAAGATAG-3’ (F)
5’-TCGCGGCAATAGATGACTAC-3’ (R)
5’-AAGCTCTTCCTCTGCATTGC-3’ (F)
5’-TGCTGGAAACGCTCTCTGTA-3’ (R)
5’-TTCGGACAGCCGTTGTCCAACACAAG-3’ (F)
5’-CCACCAATGTTCTCTTGCAGACATATTG-3’ (R)
5’-FAM/AGCCTACCT/ZEN/TGACAAGCAGTC/3IABkFQ/
5’-TCAGCGATCTCTCCACCAAAG-3’ (F)
5’-GGGTCAGCACGTTTGTCATTG-3’ (R)
5’-FAM/TGCCCGACC/ZEN/ATGGGAGAAGCTC/3IABkFQ/
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Table S2. Sources and properties of the compounds used in this study.
Compound
name
Camostat
mesylate
Bafilomycin A

Source

Function

Reference

Tocris Bioscience

TMPRSS2 inhibitor

(9), (10)

Sigma Aldrich

(7)

Apilimod
E64D

A gift of Sean
Whelan
Sigma Aldrich

Inhibits receptor mediated
endocytosis
Inhibits PIKfyve kinase and
endosomal trafficking
Inhibits cathepsins B and L

EIPA
Dynasore

Sigma Aldrich
Sigma Aldrich

(11)
(11)

Latrunculin B
Remdesivir

Sigma Aldrich
A gift of Gaya
Amarasinghe
Custom synthesis

Inhibits macropinocytosis
inhibits dymanin and clathrinmediated endocytosis
Inhibits actin polymerization
RNA-dependent RNA polymerase
Inhibits HIV-1 capsid stability

(12, 13)

NIH AIDS
Reagents
NIH AIDS
Reagents
NIH AIDS
Reagents

HIV-1 non-nucleoside reverse
transcriptase inhibitor (NNRTI)
HIV-1 nucleoside reverse
transcriptase inhibitor (NRTI)
Integrase strand transfer inhibitor

(14)

Custom synthesis
Custom synthesis
NIH AIDS
Reagents

Allosteric integrase inhibitor
Allosteric integrase inhibitor
HIV-1 protease inhibitor

(18)
(19)
(20)

Compound 1
Nevirapine
Azidothymidine
(AZT)
Raltegravir
ALLINI-2
BI-D
Amprenavir
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(6, 7)
(7)

(5)

(15, 16)
(17)
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Chapter 5: Summary and Future Studies
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5.1 Summary
This thesis dissertation presents the findings of several studies on the molecular mechanisms that
regulate the binding between integrase and the viral genomic RNA in HIV-1 and other
retroviruses. The second chapter of the dissertation elaborates the findings that integrase binding
to RNA is mediated by electrostatic interactions. The third chapter provides evidence from CLIP
showing that integrase has higher binding affinity to purine-rich sequences of RNA and the
binding is conserved in different retrovirus genera. The fourth chapter demonstrates an assay that
we have developed at the dawn of the COVID-19 pandemic and its use in screening new
antiviral agents against the SARS-Cov-2 virus. Altogether, these studies illustrate the molecular
properties underlying integrase-RNA binding and its role in HIV-1 virion morphogenesis.
Furthermore, we illustrate how our methods can be used to study different viruses and applied in
fighting future pandemics.

HIV-1 integrase binding to the genomic RNA is mediated by electrostatic interactions
The human immunodeficiency virus type 1 (HIV-1) is a retrovirus that has been responsible for
millions of deaths over the course of the AIDS pandemic (1, 2). HIV-1 contains two copies of
single stranded genomic RNA (gRNA) that surrounded conical capsid lattice as part of the viral
ribonucleoprotein complex (vRNP), altogether they form the viral core (1, 3, 4). Similarly to
other retroviruses, the gRNA of HIV-1 is reverse transcribed by the viral reverse transcriptase
enzyme in infected cells (5). The viral DNA is then integrated into the host chromosome in a
reaction catalyzed by the viral enzyme integrase (5). Some of the most efficient anti-HIV-1
therapies target this catalytic role of integrase (6, 7); these IN-targeting compounds, known as
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integrase strand-transfer inhibitors (INSTIs), have been essential components of anti-retroviral
regimens (7-14).
Over the years, there has been multiple lines of evidence which suggested that IN plays a
role in the maturation of viral particle maturation. A group of pleotropic mutations, known as
class II IN mutations, causes defects in virion assembly (15-28) and morphogenesis (17, 18, 2426, 29-31) without affecting the catalytic activity of IN in vitro studies. Furthermore, virions
produced from cells treated with allosteric integrase inhibitors (ALLINIs) showed a similar
characteristic eccentric morphological defect where the vRNP is mislocalized outside the capsid
lattice (29, 30, 32). In a groundbreaking study done by our lab and collaborators, it was shown
that IN binds to gRNA in mature virions, blocking IN-gRNA binding by either ALLINIs or class
II IN mutations caused formation of eccentric virion particles (31, 33, 34). ALLINIs and most
class II mutations blocked IN-gRNA binding by disrupting proper IN multimerization (33, 35,
36).
The R262, R263, R269 and the K273 are directly involved in the binding of IN to gRNA,
their mutations (R269A/K273A and R262A/R263A) inhibit IN-gRNA binding without affecting
IN multimerization (33). To understand how these residues mediate IN-gRNA, we isolated
secondary site suppressor mutations of the R269A/K273A mutation in an evolution-style serial
passaging experiment. By acquisition of additional D256N and D270N mutations, the
R269A/K273A class II mutant virus regained the ability of IN to bind gRNA and led to
formation of mature virion particles. Moreover, other mutations, such as D256R or D256K, that
restored the overall positive electrostatic charge of the IN CTD could restore IN-gRNA binding
and infectivity for the R269A/K273A and the R262A/R263A class II IN mutants. None of these
compensatory mutations affected the functional multimerization of IN, which suggests that they
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directly contribute to the binding of IN to gRNA. HIV-1 IN R269A/K273A viruses bearing the
compensatory mutations were more sensitive to ALLINIs in comparison to WT viruses,
providing the first key genetic evidence that specific IN residues required for RNA binding also
influence ALLINI activity. Supplementary structural modeling provides more insights into the
molecular dynamics underlying IN-gRNA binding and the ALLINI mechanism of action.
Altogether, this project elucidated the role of electrostatic interactions in IN-gRNA binding and
how such a property affects virus susceptivity to ALLINIs.
Molecular characterization of IN-RNA binding in HIV-1 and its conservation in
retroviruses
Prior studies have used CLIPseq to show that IN binds to genomic RNA in mature virions, and
that the binding is essential for the replication of HIV-1 viruses in target cells (31, 33, 37). These
studies showed that IN has high binding affinity for structured RNA elements of the HIV-1
genome such TAR (31). Using a modified CLIP approach and in vitro studies, we showed that
IN also has high affinity for purine-rich sequences, a characteristic feature of the HIV-1 genome.
In addition, we showed that IN could bind to packaged cellular RNAs in the absence of the viral
genome.

Although, virion morphologies are different from one retrovirus to another, the
maturation process is generally conserved (38-42). We have examined whether the IN-RNA
binding is conserved in other retroviruses and whether its role in virion maturation is conserved.
Our preliminary findings demonstrates that IN-gRNA binding is conserved in retroviruses such
as MLV, EIAV, MMTV, and MVV. Moreover, this binding can also be blocked by mutations
that are similar to HIV-1 class II mutations. In our future studies, we will examine how IN110

gRNA binding or the lack of it affects the maturation and morphologies of different retroviruses
by using electron microscopy, CLIP and other biochemical approaches as previously described
(33). Furthermore, we will investigate what gRNA sequences are bound by IN and whether
ALLINIs can block IN-gRNA binding in such retroviruses.

Altogether, our studies have improved our understanding of the molecular aspects of INgRNA binding and how they can be targeted by the new generation of IN-targeting antiretroviral
agents. In addition, we propose a series of experiments that would reveal key details of INgRNA complex structure. Finally, we have shown how our tools could be modified and deployed
to study and screen new inhibitors of the SARS-CoV-2 virus during the COVID-19 pandemic.
4.2 Future Studies
Temporal assessment of IN-RNA interaction during virion morphogenesis
After transcription and translation of viral RNAs in the host cells, viral structural proteins and
enzymes are part of two polyproteins, Gag and Gag-Pol (43-47). Gag and Gag-Pol are assembled
and released from the cell as part of immature virions, which later mature into virions where the
vRNP is enclosed a capsid lattice (48, 49). Understanding when IN binds to gRNA during this
process of virion morphogenesis would help understand how the encapsidation of the vRNP is
coordinated by IN and other gRNA-binding proteins such as NC.
To analyze whether IN-gRNA binding is initiated in producer cells or immature virions,
we will use an in-vitro PR cleavage assay to separate IN from the rest of Gag-Pol polyprotein.
We have previously developed a similar in vitro assay to study the cleavage of the host CARD8
protein by HIV-1 PR (50). Briefly, HEK293T cells will be transfected with proviral plasmids encoding
a catalytically inactive protease (PR-). Two days post transfection, cells and released immature virions
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will be UV-crosslinked as detailed in the CLIP protocol (51), then lysed and treated with recombinant
HIV-1 PR (available from NIH AIDS reagents) to cleave IN from Gag-Pol. The released IN protein will
then be immunoprecipitated and the γ-P32-ATP labelled RNA complexes will be analyzed for binding to
IN by autoradiography. Further sequencing could reveal the sequences that are bound by IN prior to
virion maturation.

Isolation and structural characterization of integrase-RNA complexes
HIV IN has three domains: N-terminal dimerization domain (NTD) that has a conserved HCCH
Zn+ binding motif, an RNase H-like catalytic core domain (CCD), and a C-terminal domain that
aids in DNA binding (18, 52-55). The IN protein has been virtually impossible to crystallize by
standard structural biology techniques due to its low solubility (54, 56-59). Nonetheless, each of
the IN domains has been purified, crystallized and characterized individually, in complex with
other proteins, or as double domain partial structure; but never in complex with RNA (18, 54, 55,
58). However, crystallization of the full-length HIV-1 IN structure has been elusive and none of
the HIV-1 double-domain partial structures has been crystallized together with DNA or RNA
(60). The absence of the integrase-viral RNA structure is not just an obstacle for understanding
the key role of integrase at virion morphogenesis, but it is also a challenge in the development of
new integrase-inhibitors.

We are developing a biochemical method that could isolate full-domain integrase with bound
RNA. This assay is based on immunoprecipitation of IN-gRNA complexes; full length IN and
bound viral RNA have previously been immunoprecipitated in CLIP assays (31, 33, 37). The
production and isolation IN-gRNA complexes is done in three steps: 1) Virion production, 2)
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Separation of the viral core on sucrose density gradients, and 3) isolation of IN-gRNA
complexes by immunoprecipitation.

1. Virion Production: HIV-1 virions are produced by transfecting 7 million HEK293T with
30µg of HIV-1 pNL4-3 plasmids. Two days after transfection, virions are concentrated
by ultracentrifugation at 28000rpm for 90 minutes on an SW32Ti rotor. The virions can
then be resuspended and lysed in 500uL of 1XPBS containing 0.5% Triton-X.
2. Separation of virion components by sucrose density sedimentation: In mature HIV-1
virions, IN-gRNA complexes are surrounded by the capsid lattice as part of the vRNP
and viral core (61, 62). Being surrounded by the capsid lattice, components of the viral
core (RT, MA, CA, and IN) move together to denser fractions during density
sedimentation (33, 63, 64). Some capsid mutations (K203A and P38A) destabilize the
capsid and lead to the mislocalization of IN-gRNA complexes and other viral core
outside of the capsid lattice (63-65). During density sedimentation, the CA, MA, and RT
of such mutant viruses migrated separately from IN-gRNA complexes (Figure 1A,B).
3. Isolation of IN-gRNA complexes by immunoprecipitation: Following density
sedimentation, the fractions containing IN-RNA complexes (7-10) are combined (Figure
1C) and Triton is added to a final concentration of 0.5% to aid in immunoprecipitation.
Furthermore, RNase A can be added to fragment RNA that is attached to the integrase.
IN complexes are then immunoprecipitated using 40µL of Protein G Dynabeads® (Life
Technologies) conjugated with a monoclonal anti-integrase mouse antibody. Following
immunoprecipitation, the beads are washed three times with 1XSTE (100 mM NaCl, 10
mM Tris-Cl (pH 8.0) to remove any contaminating proteins in complex with IN.
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Immunoblotting (Figure 1C) shows that a vast majority of integrase was
immunoprecipitated using the above approach, proving the efficiency of
immunoprecipitation technique.

Figure 1. Isolation of IN-RNA complexes. Components of envelope-stripped virions were
separated by density segmentation on a linear sucrose gradient. A, B. Migration of Capsid, Matrix,
and RT as seen in the fraction1-10 (top-bottom). C. Collective IN in fraction 7-10 (top), and
immunoprecipitated integrase from fractions 7-10 compared to integrase left in the IP solution
(Unbound)(bottom). D. Immunoprecipitated integrase was separated
from the IP antibody using immobilized Papain (top left) and Negative staining images of
integrase complexes eluted from papain beads.
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To serve as specimen for cryo-EM, the majority of the immunoprecipitated integrase had to be
removed from the immunoprecipitated beads. Immobilized papain© (Thermo Fisher Scientific
Inc 20341) fragments apart the Fc and Fab regions of most IgG antibodies and it was used to
release IN from the IP antibody. Papain was activated in a reaction buffer containing 20mM
sodium phosphate, 10mM EDTA, 20mM cysteine.HCl; pH 7.0. Cleavage by papain was done in
a thermomixer at 370C 800rpm overnight. Papain cleaved the majority of integrase away from
the antibody (Figure 1D). Diagnostic negative staining was done for initial inquiries on whether
the purified complexes were the size of integrase or met the quantity. Negative staining showed
that there was a good yield of IN complexes (Figure 1D). RNAseA did not seem to alter the size
of the complexes (Fig. 1D); however, P38A particles generated slightly smaller and more
uniform complexes, which are more suitable for mass spectrometry and Cryo EM (Figure 1D).
Future experiments will make a definitive confirmation on whether the complexes observed by
negative staining were integrase complexes by using mass spectrometry. The structure of these
complexes will then be studied by small-particle cryo-EM using facilities at the Washington
University School of Medicine.
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